US Pat. No. 10,137,201

PROCESS FOR FORMULATING AN ANIONIC AGENT

DICERNA PHARMACEUTICALS, ...

1. A method of producing a particle comprising an anionic agent the method comprising:(a) combining in an acidic aqueous solution (i) a modified lipid which prevents particle aggregation during lipid-anionic agent particle formation and (ii) a cationic lipid, in an amount sufficient for a complex to form;
(b) combining the complex of step (a) with an anionic agent;
(c) combining a neutral aqueous solution with the complex-anionic agent of step (b) to form a complex-anionic agent aqueous suspension;
(d) forming a solution or suspension comprising an alcohol and at least one lipid selected from the group consisting of a neutral lipid, a sterol, a cationic lipid and a modified lipid which prevents particle aggregation during lipid-anionic agent particle formation; and
(e) adding the solution or suspension of step (d) to the complex-anionic agent aqueous suspension of step (c), thereby causing the concentration of the alcohol in the complex-anionic agent aqueous suspension to gradually increase from 0% to up to no more than 40% (v/v) as more of the solution of step (d) is added to the complex-anionic agent aqueous solution of step (c), thereby producing a particle comprising an anionic agent.
US Pat. No. 10,137,202

ANTIBODY-DRUG CONJUGATES AND IMMUNOTOXINS

Oncomatryx Biopharma, S.L...

1. A conjugate having the formula I:A-(L-D)p  (I)
or a pharmaceutically acceptable salt or solvate thereof,
wherein:
A is an antibody that selectively binds fibroblast activation protein alpha (FAP), said antibody comprising heavy chain complementarity determining regions 1-3 (CDRH1-3) and light chain complementarity determining regions 1-3 (CDRL1-3) having the following amino acid sequences:
(i) CDRH1: SEQ ID NO: 7;
(ii) CDRH2: SEQ ID NO: 8;
(iii) CDRH3: SEQ ID NO: 9;
(iv) CDRL1: SEQ ID NO: 10;
(v) CDRL2: SEQ ID NO: 11; and
(vi) CDRL3: SEQ ID NO: 12;
L is a linker;
D is a drug comprising a cytolysin; and
p is 1 to 10.
US Pat. No. 10,137,203

HER2 APTAMER-ANTICANCER DRUG COMPLEX FOR CANCER CELL CHEMOTHERAPY

Korea University Research...

1. A method of manufacturing a complex for cancer cell chemotherapy, comprising:a) preparing a nucleic acid aptamer consisting of the base sequence of SEQ ID NO:1 for specifically binding to HER2; and
b) forming an aptamer-anticancer drug complex by reacting the aptamer with anticancer drug DM1;
wherein the aptamer includes a thiol group introduced at the 3? terminal end and DM1 includes a thiol group such that a disulfide bond is formed between the aptamer and DM1.
US Pat. No. 10,137,204

ANTI-DLL3 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER

AbbVie Stemcentrx LLC, N...

1. A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of an anti-DLL3 antibody drug conjugate (ADC), wherein the antibody drug conjugate (ADC) comprises the formula M-[L-D]n, wherein:M comprises an anti-DLL3 antibody that binds to an epitope within the DSL domain of a DLL3 protein set forth as SEQ ID NO: 3 or 4;
L comprises an optional linker;
D comprises a radioisotope; and
n is an integer from 1 to 20.
US Pat. No. 10,138,485

NEUTRAL NANOTRANSPORTERS

RXi Pharmaceuticals Corpo...

1. A composition comprising:a hydrophobic modified polynucleotide, wherein the hydrophobic modified polynucleotide comprises an isolated double stranded nucleic acid molecule comprising a guide strand and a passenger strand, wherein the isolated double stranded nucleic acid molecule includes a double stranded region and a single stranded region, wherein the double stranded region is from 8-14 nucleotides long, wherein the single stranded region is at the 3? end of the guide strand and is 4-12 nucleotides long, wherein the single stranded region contains 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 phosphorothioate modifications, wherein at least 40% of the nucleotides of the isolated double stranded nucleic acid molecule are modified, and wherein a hydrophobic conjugate is attached to the isolated double stranded nucleic acid molecule at the 3? end of the sense strand, and wherein the isolated double stranded nucleic acid molecule does not form a hairpin;
a neutral fatty mixture comprising at least 20% dioleoylphosphatidylcholine (DOPC) or distearoylphosphatidylcholine (DSPC), and at least 20% sterol; and
optionally a cargo molecule,
wherein the hydrophobic modified polynucleotide and the neutral fatty mixture forms a micelle.
US Pat. No. 10,137,205

THYMIDYLATE KINASE FUSIONS AND USES THEREOF

University Health Network...

1. A composition comprising:(a) a stably integrating delivery vector;
(b) a polynucleotide encoding a modified human thymidylate kinase (tmpk), wherein the modified human tmpk increases phosphorylation of 3?-azido-3?-deoxythymidine (AZT) relative to phosphorylation of AZT by wild-type human tmpk; and
(c) a polynucleotide encoding a detection cassette polypeptide that is expressed on the surface of a cell, wherein the polynucleotide encoding the detection cassette polypeptide is fused to the polynucleotide encoding the modified human tmpk and the detection cassette polypeptide is fused to the modified human tmpk;
wherein the modified human tmpk comprises a modification selected from the group consisting of (i) a F to Y mutation at amino acid position 105 of SEQ ID NO: 11; (ii) a R to G mutation at amino acid position 16 of SEQ ID NO: 12; and (iii) a R to A mutation at amino acid position 200 of SEQ ID NO: 16.
US Pat. No. 10,138,486

INHIBITORS OF DEK PROTEIN AND RELATED METHODS

THE REGENTS OF THE UNIVER...

1. A method of treating or ameliorating an inflammatory condition in a patient, comprising administering to said patient a therapeutically effective amount of a single-stranded anti-DEK DNA aptamer, and a pharmaceutically acceptable carrier, wherein said anti-DEK DNA aptamer is SEQ ID NO:1, SEQ ID NO: 2 or SEQ ID NO:6.
US Pat. No. 10,137,206

NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF

FACTOR BIOSCIENCE INC., ...

1. A method for treating a subject, comprising administering a synthetic RNA encoding a gene-editing protein targeting an immune checkpoint molecule gene, wherein the gene-editing protein comprises:(a) a DNA-binding domain comprising a plurality of repeat sequences and at least one of the repeat sequences comprises the amino acid sequence: LTPvQWAlAwxyzGHGG (SEQ ID NO: 629) and is between 36 and 39 amino acids long, wherein:
“v” is Q, D or E,
“w” is S or N,
“x” is H, N, or I,
“y” is D, A, I, N, G, H, K, S, or null, and
“z” is GGKQALETVQRLLPVLCQD (SEQ ID NO: 630) or GGKQALETVQRLLPVLCQA (SEQ ID NO: 631); and
(b) a nuclease domain comprising a catalytic domain of a nuclease.
US Pat. No. 10,138,488

CANCER VACCINE FOR DOGS

INVECTYS, Paris (FR)

1. A nucleic acid molecule that comprises a sequence encoding a fusion protein which comprises at least 80% of the amino acid sequence of a full length wild-type dog telomerase reverse transcriptase (TERT), wherein said protein (i) does not contain amino acids VDD within the TERT catalytic site, (ii) does not contain a nucleolar localization signal sequence, and (iii) comprises an amino acid sequence which enhances the addressing of said TERT to a proteasome.
US Pat. No. 10,137,208

VIVO TUMOR TARGETING AND SPECTROSCOPIC DETECTION WITH SURFACE-ENHANCED RAMAN NANOPARTICLE TAGS

Emory University, Atlant...

1. A surface-enhanced Raman spectroscopic active composite nanostructure comprising:a single-core metallic nanoparticle with a diameter of 100 nm or less;
a Raman reporter molecule disposed on the surface of the core; and
an encapsulating protective layer disposed on the surface of the core and the reporter molecule, wherein the encapsulating protective layer is a thiolpolyethylene glycol, and wherein the encapsulated reporter molecule has a measurable surface-enhanced Raman spectroscopic signature.
US Pat. No. 10,138,489

CYANOBACTERIAL STRAINS CAPABLE OF UTILIZING PHOSPHITE

Algenol Biotech LLC, For...

1. A genetically modified cyanobacterial cell for the production of a product of interest, comprising:a) at least one recombinant gene that encodes a heterologous phosphite dehydrogenase enzyme EC:1.20.1.1 that catalyzes the oxidation of phosphite to phosphate, wherein said enzyme has at least 85% identity to the protein sequence of the Ralstonia phosphite dehydrogenase enzyme (SEQ ID NO: 12);
b) an operon comprising at least one recombinant phosphite transporter gene encoding at least one phosphite transporter protein for transporting phosphite into the cell wherein the at least one phosphite transporter protein has at least 85% identity to a protein sequence selected from the group consisting of Cyanothece PtxA (SEQ ID NO: 19), Cyanothece PtxB (SEQ ID NO:22), Cyanothece PtxC (SEQ ID NO: 25), and Desulfotignum phosphitoxidans PtdC (SEQ ID NO: 28);
c) a knockout or knockdown of a gene encoding an endogenous protein having at least 85% identity to the repressor protein PhoU; and
d) at least one recombinant production gene encoding a polypeptide for the production of said product of interest.
US Pat. No. 10,138,490

TRANSFORMED PLANTS TOLERANT TO HERBICIDES DUE TO OVEREXPRESSION OF PREPHENATE DEHYDROGENASE AND P-HYDROXYPHENYLPYRUVATE DIOXYGENASE

1. A method for cultivating a transformed plant, the method comprisinga) planting a seed of the transformed plant,
b) contacting the seed or a transformed plant grown from the seed with a herbicidal composition comprising an inhibitor of p-hydroxyphenylpyruvate dioxygenase, and
c) cultivating the plant, wherein the transformed seed or the transformed plant is substantially unaffected by the herbicidal composition, wherein the plant comprises:
(1) a first gene that is functional in a plant, wherein the first gene comprises a nucleotide sequence that encodes a yeast prephenate dehydrogenase, and
(2) a second gene that is functional in a plant, wherein the second gene comprises a nucleotide sequence that encodes a p-hydroxyphenylpyruvate dioxygenase, and
wherein the plant overexpresses the prephenate dehydrogenase and the p-hydroxyphenylpyruvate dioxygenase, and wherein said plant is tolerant to an amount of said inhibitor that is toxic to or decreases the growth of plants transformed with said second gene alone.
US Pat. No. 10,138,234

2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-A]PYRIDINE DERIVATIVES

Hoffmann-La Roche Inc., ...

1. A compound selected from the group consisting of:N-(2-fluoroethyl)-2-phenylimidazo[1,2-a]pyridin-7-amine,
N-(2-fluoroethyl)-N-methyl-2-phenylimidazo[1,2-a]pyridin-7-amine,
N,N-dimethyl-2-phenylimidazo[1,2-a]pyridin-7-amine,
N-methyl-2-phenylimidazo[1,2-a]pyridin-7-amine,
[2-(4-dimethylamino-phenyl)-imidazo[1,2-a]pyridin-7-yl]-dimethyl-amine,
(2-[4-(2-fluoro-ethoxy)-phenyl]-imidazo[1,2-a]pyridin-7-yl}-dimethyl-amine,
[2-(4-fluoromethoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-dimethyl-amine,
[2-(4-methoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-dimethyl-amine,
N-methyl-2-m-tolylimidazo[1,2-a]pyridin-7-amine,
N,N-dimethyl-(2-m-tolyl-imidazo[1,2-a]pyridin-7-yl)-amine,
N,N-dimethyl-(2-p-tolyl-imidazo[1,2-a]pyridin-7-yl)-amine,
N-methyl-(2-p-tolyl-imidazo[1,2-a]pyridin-7-yl)-amine,
N-(2-fluoroethyl)-N-methyl-(2-p-tolyl-imidazo[1,2-a]pyridin-7-yl)-amine,
2-(4-(dimethylamino)phenyl)-N-(2-fluoroethyl)-N-methylimidazo[1,2-a]pyridin-7-amine,
[2-(3-methoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-dimethyl-amine,
(2-fluoro-ethyl)-methyl-(2-m-tolyl-imidazo[1,2-a]pyridin-7-yl)-amine
[2-(3-methoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
[2-(4-fluoromethoxy-phenyl)-imidazo[1,2-a]pyri din-7-yl]-methyl-amine,
(2-fluoro-ethyl)-(2-p-tolyl-imidazo[1,2-a]pyridin-7-yl)-amine,
(2-fluoro-ethyl)-(2-m-tolyl-imidazo[1,2-a]pyridin-7-yl)-amine,
(2-fluoro-ethyl)-[2-(4-fluoromethoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
[2-(3,4-dimethyl-phenyl)-imidazo[1,2-a]pyridin-7-yl]-dimethyl-amine,
[2-(3,4-dimethyl-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
[3H]-[2-(4-fluoromethoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
[3H]—N-methyl-2-phenyl-imidazo[1,2-a]pyridin-7-amine,
[3H]—N-(2-fluoroethyl)-2-phenyl-imidazo[1,2-a]pyridin-7-amine,
[3H]—N-methyl-(2-p-tolyl-imidazo[1,2-a]pyridin-7-yl)-amine,
(2-fluoro-ethyl)-[2-(4-methoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
[2-(3,4-dimethoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
cyclopropyl-[2-(4-methoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
methyl-[2-(4-methyl sulfanyl-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
[2-(3,4-dimethyl-phenyl)-imidazo[1,2-a]pyridin-7-yl]-(2-fluoro-ethyl)-amine,
[2-(3,4-dimethoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-(2-fluoro-ethyl)-amine,
[2-(4-methoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
(2-fluoro-ethyl)-[2-(4-methoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
(2-fluoro-ethyl)-[2-(3-methoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
[2-(3-fluoromethoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-dimethyl-amine,
(2-fluoro-ethyl)-[2-(4-methyl sulfanyl-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
cyclopropyl-[2-(4-fluoromethoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
2-methoxy-4-(7-methylamino-imidazo[1,2-a]pyridin-2-yl)-phenol,
3-(7-dimethylamino-imidazo[1,2-a]pyridin-2-yl)-phenol,
[4-[7-(methylamino)imidazo[1,2-a]pyridin-2-yl]phenyl]methanol,
[4-[7-(dimethylamino)imidazo[1,2-a]pyridin-2-yl]phenyl]methanol,
2-(3,5-dimethoxyphenyl)-N-methylimidazo[1,2-a]pyridin-7-amine,
N-[2-(4-ethoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
methyl-[2-(4-pyrrolidin-1-yl-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
N-[2-(3-fluoro-4-methoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
N-[2-(4-diethylamino-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
N-[2-(4-ethyl-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
2-[4-(methoxymethyl)phenyl]-N,N-dimethyl-imidazo[1,2-a]pyridin-7-amine,
methyl-[2-(4-morpholin-4-yl-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
2-[4-(2-fluoroethoxymethyl)phenyl]-N,N-dimethyl-imidazo[1,2-a]pyridin-7-amine,
2-(3-methoxy-4-methylphenyl)-N-methylimidazo[1,2-a]pyridin-7-amine,
2-[4-(2-fluoroethoxy)phenyl]-N-methylimidazo[1,2-a]pyridin-7-amine,
2-(4-(benzyl(methyl)amino)phenyl)-N-methylimidazo[1,2-a]pyridin-7-amine,
N-[2-(4-difluoromethoxy-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
N-[2-(4-bromo-phenyl)-imidazo[1,2-a]pyridin-7-yl]-methyl-amine,
methyl-[2-(4-piperidin-1-yl-phenyl)-imidazo[1,2-a]pyridin-7-yl]-amine,
2-(7-methylamino-imidazo[1,2-a]pyridin-2-yl)-phenol,
methyl 3-[7-(methylamino)imidazo[1,2-a]pyridin-2-yl]benzoate,
[3-[7-(methylamino)imidazo[1,2-a]pyridin-2-yl]phenyl]methanol,
N-cyclopropyl-2-[4-(2-fluoroethoxy)phenyl]imidazo[1,2-a]pyridin-7-amine,
7-(azetidin-1-yl)-2-[4-(3-fluoropropoxy)phenyl]imidazo[1,2-a]pyridine,
4-methyl-2-(7-methylamino-imidazo[1,2-a]pyridin-2-yl)-phenol,
2-[3-(methoxymethyl)phenyl]-N-methyl-imidazo[1,2-a]pyridine-7-amine,
2-(4-(2-fluoroethylamino)phenyl)-N-methylimidazo[1,2-a]pyridin-7-amine,
N-(3-fluoropropyl)-2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-7-amine,
2-(3-(fluoromethoxy)phenyl)-N-methylimidazo[1,2-a]pyridin-7-amine,
2-(2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-7-ylamino)propan-1-ol,
N-(2-fluoroethyl)-2-(3-methoxy-4-methylphenyl)imidazo[1,2-a]pyridin-7-amine,
N-methyl-2-(3-(methylthio)phenyl)imidazo[1,2-a]pyridin-7-amine,
2-(3-(2-fluoroethoxy)phenyl)-N-methylimidazo[1,2-a]pyridin-7-amine,
2-(3-(3-fluoropropoxy)phenyl)-N-methylimidazo[1,2-a]pyridin-7-amine,
2-(4-(4-fluoropiperidin-1-yl)phenyl)-N-methylimidazo[1,2-a]pyridin-7-amine,
4-(7-(2-fluoroethylamino)imidazo[1,2-a]pyridin-2-yl)-2-methoxyphenol,
4-(7-(2-fluoroethylamino)imidazo[1,2-a]pyridin-2-yl)phenol,
3-(7-(2-fluoroethylamino)imidazo[1,2-a]pyridin-2-yl)phenol,
N-(2-fluoroethyl)-2-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyridin-7-amine, and
N-cyclopropyl-2-[4-(3-fluoropropoxy)phenyl]imidazo[1,2-a]pyridin-7-amine, or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,138,491

PROTEIN HAVING GLYCOALKALOID BIOSYNTHETIC ENZYME ACTIVITY AND GENE ENCODING THE SAME

KIRIN HOLDINGS KABUSHIKI ...

1. A transformed solanaceous plant having reduced glycoalkaloid content in which the expression of a gene encoding a protein having glycoalkaloid biosynthetic enzyme activity is suppressed, wherein the suppression of the gene is induced by RNAi, and wherein the gene comprises a DNA selected from the group consisting of (a) to (c);(a) DNA consisting of the nucleotide sequence shown in SEQ ID NO: 2, 4, 19 or 21;
(b) DNA that consists of a nucleotide sequence having 90% or more sequence identity to the nucleotide sequence shown in SEQ ID NO: 2, 4, 19 or 21; and
(c) DNA consisting of a degenerate isomer of the nucleotide sequence shown in SEQ ID NO: 2, 4, 19 or 21.
US Pat. No. 10,139,003

LIP SEAL FOR WATER PUMP

Eagle Industry Co., Ltd.,...

1. A lip seal for water pump made of a rubber-like elastic material, fixed to a housing as a fixed side and in sliding contact with a shaft rotating relative to the housing;the lip seal having sliding surface with a surface roughness Ra (according to JIS B0601 corresponding to ISO 4287) of 1 to 30 ?m, being obtained by vulcanization-molding of a rubber composition comprising 100 parts by weight of hydrogenated nitrile rubber or EPDM, 1 to 150 parts by weight of a reinforcing filler, 5 to 90 parts by weight of a non-reinforcing filler having an average particle diameter of 1 ?m or more, 0.1 to 5 parts by weight of a coupling agent, 1 to 15 parts by weight of a co-crosslinking agent, and 0.5 to 10 parts by weight of an organic peroxide.
US Pat. No. 10,138,492

NUCLEOTIDE SEQUENCES AND CORRESPONDING POLYPEPTIDES CONFERRING IMPROVED NITROGEN USE EFFICIENCY CHARACTERISTICS IN PLANTS

Ceres, Inc., Thousand Oa...

1. A method of producing a plant, said method comprising(a) growing a plant cell comprising an exogenous nucleic acid, said exogenous nucleic acid comprising a regulatory region operably linked to a nucleotide sequence, said nucleotide sequence comprising 95 percent or greater sequence identity to the nucleotide sequence of SEQ ID NO:48, or wherein said nucleotide sequence encodes a polypeptide comprising 95 percent or greater sequence identity to the amino acid sequence of SEQ ID NO:49;
(b) growing a plant from said plant cell; and
(c) selecting for a plant comprising an increased level of low-nitrogen tolerance as compared to the corresponding level of low-nitrogen tolerance of a control plant that does not comprise said nucleic acid.
US Pat. No. 10,138,493

SYNTHETIC TRANSCRIPTIONAL AND EPIGENETIC REGULATORS BASED ON ENGINEERED, ORTHOGONAL ZINC FINGER PROTEINS

TRUSTEES OF BOSTON UNIVER...

1. An engineered responsive promoter comprising (a) at least one target DNA sequence element selected from the group consisting of 5?-CGTCGAAGTCGAAGTCGACC-3? (SEQ ID NO: 81), 5?-GGACGACGTTACGGACGTAC-3? (SEQ ID NO: 82), 5?-A GACGTCGAAGTAGCCGTAG-3? (SEQ ID NO: 83), 5?-GGACGACGCCGATGTAGAAG-3? (SEQ ID NO: 84), 5?-TGAAGCAGTCGACGCCGAAG-3? (SEQ ID NO: 85), 5?-GGACGACGCGGTCTAAGAAG-3? (SEQ ID NO: 86), 5?-CGACGAGGTCGCATAAGTAG-3? (SEQ ID NO: 87), 5?-AGACGCAGTATAGGTCGAAC-3? (SEQ ID NO: 88), 5?-AGACGCAGTATAGGACGACG-3? (SEQ ID NO: 89), 5?-CGGCGTAGCCGATGTCGCGC-3? (SEQ ID NO: 90), and 5?-GGTCGTTGCGGTAGTCGAAG-3? (SEQ ID NO: 91) and (b) a promoter sequence, wherein the at least one target DNA sequence element is operably linked at the 5? end of the promoter sequence in order to influence transcription initiation of a nearby coding sequence.
US Pat. No. 10,136,957

LEAK RESISTANT ARTICLE

Ansell Limited, Victoria...

1. A leak-resistant elastomeric barrier comprising:an elastomeric barrier comprising elastomeric polymer, having two sides, and coated on at least a portion of a first side with highly hydrophobic coating such that the initial contact angle with water at 23±2° C. is about 130° or more, and that contact angle does not decay by more than about 10% over 40 minutes.
US Pat. No. 10,141,572

CATHODE ACTIVE MATERIALS FOR LITHIUM-ION BATTERIES

Apple Inc., Cupertino, C...

1. A compound represented by Formula (III):Li?Co1?xMxAl?O?  (III)
wherein:
M is Mn,
0.95???1.10,
0 0 1.95???2.60.
US Pat. No. 10,138,495

BIO-PRODUCTION OF LENTIVIRAL VECTORS

Calimmune, Inc., Tucson,...

1. A recombinant plasmid comprising a nucleotide sequence having at least 90% identity to the sequence of SEQ ID NO: 1.
US Pat. No. 10,137,215

ORGANIC WASTE ODOR ABSORBER

1. A method of treating organic waste comprising:a step of placing a composition within a receptacle to create a layer on the bottom of said receptacle;
a step of placing organic waste within said receptacle already containing the layer of said composition, where said organic waste is placed on top of said composition;
a step of placing additional said composition on top of said organic waste within said receptacle;wherein said composition's materials comprise:a. 35% to 85% holocellulose, by weight
b. 8% to 30% lignin, by weight
c. 40% to 80% silica, by weight;wherein said composition comprises dried materials;wherein said composition's materials comprise a particle size range from 0.002 millimeters in diameter to 300 by 300 by 300 millimeters;wherein said composition comprises a scent;wherein said organic waste is composted.
US Pat. No. 10,138,239

PREPARATION METHOD OF CRYSTALLINE FORM A OF PCI-32765

Crystal Pharmatech Co. LT...

1. A preparation method of PCI-32765 crystalline Form A wherein the preparation method comprises the following steps:1) preparing a PCI-32765 free base solution by dissolving the free base solid of PCI-32765 in a solvent;
2) adding dropwise the solution prepared by step 1) into an anti-solvent at a temperature of 0-20° C., then stirring the mixture at a temperature of 0-20° C. and adding seed crystals of PCI-32765 Form A to form a suspension; or adding dropwise the solution prepared by step 1) into a suspension containing seed crystals of PCI-32765 Form A at a temperature of 0-20° C. to form a suspensions;
3) continuously stirring the suspension obtained by step 2) and aging the suspension until a crystal slurry is obtained;
4) filtering the crystal in step 3) to obtain a filter cake, then washing and drying the filter cake to obtain a powder of PCI-32765 crystalline Form A.
US Pat. No. 10,138,496

VECTORS WITH MODIFIED INITIATION CODON FOR THE TRANSLATION OF AAV-REP78 USEFUL FOR PRODUCTION OF AAV

uniQure IP B.V., Amsterd...

1. A method of producing a recombinant parvoviral viron in an insect cell comprising, transfecting and insect cell with a nucleotide sequence encoding parvoviral Rep proteins Rep78 and Rep52, the nucleotide sequence comprising a Rep78 coding sequence and a Rep52 coding sequence, the Rep78 coding sequence and the Rep52 coding sequence being operably linked to expression control sequences for expression of both a Rep78 protein and a Rep52 protein in an insect cell; wherein the Rep52 coding sequence is comprised within the Rep78 coding sequence, and wherein a molar ratio of Rep78 and Rep52 in the range of 1:10 to 10:1 is produced when the nucleotide sequence is expressed in the insect cell.
US Pat. No. 10,141,574

CARBON NANOTUBE DISPERSION LIQUID AND MANUFACTURING METHOD THEREOF

LG CHEM, LTD., Seoul (KR...

1. A carbon nanotube dispersion comprising:bundle-type carbon nanotubes;
a dispersion medium; and
partially hydrogenated nitrile rubber having a residual double bond (RDB) value of 0.5% by weight to 40% by weight calculated according to the following Mathematical Formula 1,
wherein dispersed particle diameters of the carbon nanotubes have a particle size distribution D50 of 3 ?m to 10 ?m:
RDB (% by weight)=BD weight/(BD weight+HBD weight)×100  [Mathematical Formula 1]
in Mathematical Formula 1, BD is a conjugated diene-derived structure unit and HBD is a hydrogenated conjugated diene-derived structure unit.
US Pat. No. 10,138,498

RECOMBINANT MICROORGANISMS FOR ENHANCED PRODUCTION OF MEVALONATE, ISOPRENE, AND ISOPRENOIDS

Danisco US Inc., Palo Al...

1. Recombinant bacterial or yeast cells capable of increased production of isoprenoids, wherein the cells are engineered by(i) modulation of citrate synthase activity such that the activity of citrate synthase is Decreased;
(ii) modulation of the activities of one or more of the following enzymes such that:
(a) phosphotransacetylase activity is attenuated;
(b) acetate kinase activity is attenuated; and/or
(c) lactate dehydrogenase activity is attenuated; and
(iii) modulation of the activity of two or more of the following enzymes such that (d) malate dehydrogenase activity is increased, (e) pyruvate dehydrogenase activity is increased, and/or (f) phosphoenolpyruvate carboxylase activity is attenuated, resulting in increased carbon flux towards mevalonate production;
wherein the cells further comprise (A) one or more nucleic acids encoding one or more mevalonate (MVA) pathway polypeptides; and (B) one or more nucleic acids encoding a polyprenyl pyrophosphate synthase; and
wherein the cells produce increased amounts of isoprenoids compared to isoprenoid-producing cells that do not comprise (i-iii).
US Pat. No. 10,137,218

DISINFECTION SYSTEM OF CONTACT LENS

MENICON CO., LTD., Nagoy...

1. A method for disinfecting a contact lens comprising:contacting a contact lens with a contact lens disinfecting solution having a pH of from 6 to 8 and including 1 to 10% hydrogen peroxide and 0.1% to 5% by weight of at least one of an organic carboxylic acid and a salt thereof, wherein the organic carboxylic acid includes a structure in which a hydroxyl group and a carboxyl group are bonded to one carbon atom, and
neutralizing the hydrogen peroxide in the disinfecting solution by contacting the disinfecting solution with a metal catalyst for a treatment duration in which the level of hydrogen peroxide in the disinfecting solution is reduced to a concentration of 200 ppm or less, the treatment duration being a shorter time period than a period that would otherwise be required to neutralize hydrogen peroxide to the same concentration with the metal catalyst in a like contact lens disinfecting solution without the organic carboxylic acid.
US Pat. No. 10,138,499

METHODS FOR IMPROVING THE EFFICIENCY OF SIMULTANEOUS SACCHARIFICATION AND FERMENTATION REACTIONS

DANISCO US INC., Palo Al...

1. A method for simultaneous saccharification and fermentation (SSF) comprising culturing a complete fermentation medium, said complete fermentation medium comprising at least one fermenting microorganism, at least one xylan-containing biomass, at least one cellulase, at least one hemicellulase, at least one retaining ?-xylosidase, and at least one inverting ?-xylosidase, for a period and under conditions suitable for producing a fermentation product, which is an alcohol, wherein the at least one inverting ?-xylosidase comprises an Fv43D polypeptide having at least 90% sequence identity to SEQ ID NO:2, or to residues 21 to 350 of SEQ ID NO:2, and the complete fermentation medium comprises a greater amount of the at least one inverting ?-xylosidase than that of the at least one retaining ?-xylosidase on a mole basis.
US Pat. No. 10,137,475

COATING SYSTEM, A METHOD OF APPLYING THE COATING SYSTEM AND AN ARTICLE COMPRISING THE COATING SYSTEM

Dow Global Technologies L...

1. A method of applying a multi-layer coating system comprising:(I) selecting an epoxy formulation which comprises
(a1) epoxy resin;
(a2) curing agent selected from the group consisting of amine adducts, amides, polyamides, and Mannich bases derived from polyfunctional amines with no more than 4.5 wt % free amine based on a weight solids of the curing agent; and
(II) applying the epoxy formulation onto a substrate;
(III) fully or partially curing the epoxy formulation to produce an epoxy coating layer;
(IV) selecting a non-isocyanate polyurethane formulation;
(V) applying the non-isocyanate polyurethane formulation onto the epoxy coating layer; and
(VI) allowing the topcoat formulation and epoxy formulation to fully cure thereby forming a multi-layer coating system;
wherein the epoxy formulation and/or non-isocyanate polyurethane formulation optionally further comprise one or more additives selected from the group consisting of solvent, reactive diluent, plasticizer, pigment, filler; rheology modifiers, dispersants, surfactants, UV stabilizers, and corrosion inhibitors.
US Pat. No. 10,138,500

D-LACTIC ACID-PRODUCING STRAIN AND USE THEREOF

CJ CHEIJEDANG CORPORATION...

1. A D-lactic acid-producing strain modified to attenuate or inactivate L-lactate dehydrogenase (L-LDH) activity and to enhance D-lactate dehydrogenase (D-LDH) activity, wherein the D-lactic acid-producing strain so modified is a Lactobacillus sp strain which produces more L-lactic acid than D-lactic acid prior to said modification; wherein the L-LDH activity is derived from a L-LDH-encoding polynucleotide from Lactobacillus paracasei, Lactobacillus casei, or Lactobacillus rhamnosus; wherein the D-LDH activity is derived from a D-LDH-encoding polynucleotide from Lactobacillus plantarum or Lactobacillus delbrueckii; and wherein the Lactobacillus sp. strain is selected from the group consisting of Lactobacillus casei, Lactobacillus paracasei, and Lactobacillus rhamnosus.
US Pat. No. 10,136,708

LIGHT PRECIOUS ALLOY OF GOLD AND TITANIUM AND COMPONENTS FOR TIMEPIECES OR JEWELLERY MADE FROM SUCH A LIGHT PRECIOUS ALLOY OF GOLD AND TITANIUM

1. A light, precious gold-titanium based alloy comprising, by mass, from 750‰ to 780‰ of gold,wherein said alloy has the following composition formula:
TiaAubMcTd
where a b, c, d are atomic proportions such that:
a+b+c+d=1,
0.45?a?0.55; 0.41?b?0.495; 0.025?c?0.13; 0.001?d?0.025,
wherein M represents at least one element selected from the group consisting of Nb, V, Pd, Pt, and Fe, and
T represents boron and optionally an additional element, and
wherein the additional element is selected from the group consisting of Nb, V, Pd, Pt, Fe, Mo, Ta, W, Co, Ni, Ru, Rh, Ir, Cr, Mn, Cu, Zn, Ag, Al, Si, Ge, Sn, Sb, and In,
M and T are different elements, and
the alloy comprises the boron as T or as a part of T in an atomic content of from 0.03% to 0.3%.
US Pat. No. 10,137,220

HEMOSTATIC COMPOSITION

Omrix Biopharmaceuticals ...

1. A hemostatic composition comprising:a) cellulose-based fibers having a size distribution of D90 of less than 350 ?m, and D50of less than 167?m, the fibers are at a concentration range of 83.5%-90.0% w/w of the entire composition;
b) an omega amino carboxylic acid at a concentration range of 2.5%-5.0% w/w of the entire composition;
c) protamine salt at a concentration range of 2.5%-5.0% w/w of the entire composition;
d) a calcium chloride divalent cation, the cation concentration being 1.3%-1.8% w/w of the entire composition,
wherein the composition is in the form of a powder and/or aggregates and forms a resistant gel upon contact with blood.
US Pat. No. 10,137,476

COATING AGENT FOR CORROSION-RESISTANT COATINGS

1. A multicoat color and/or effect paint system comprising, lying above one another in this order,(1) at least one first basecoat comprising a basecoat material (A);
(2) a second color and/or effect basecoat comprising a basecoat material (B); and
(3) at least one transparent coating comprising a clearcoat material (C);
wherein the basecoat material (A) comprises:
(a.1) at least one binder,
(a.2) at least one color or effect pigment, and
(a.3) at least one water-soluble or water-dispersible, corrosion-inhibiting, oligomeric or polymeric component comprising:
a parent structure (GK) comprising at least two repeating monomer units (ME) and
at least one uni- and/or multidentate, potentially anionic ligand (L) capable of forming complexes after the multicoat paint system has been thermally cured,
wherein the monomer units (ME) are ethylenimines units and the ligand (L) is hydroxyacetophenone.
US Pat. No. 10,138,501

METHOD FOR PREPARING DIGLYCERIDE USING BUBBLE COLUMN REACTOR

Jinan University, Guangz...

1. A method for synthesizing diglyceride using a bubble column reactor, characterized by comprising the steps of:(1) placing an immobilized enzyme on the bearing mechanism of the bubble column reactor, and a hot bath mechanism is actuated to heat the reactor body to 55-75° C.;
(2) adding glycerol and fatty acid in a feed chute as reactants, and water is added as an activating enzyme catalyst; wherein the molar ratio of glycerol and fatty acid is 1:1-10:1; the added amount of water is less than 10% of the total mass of the reactants; and the added amount of the immobilized enzyme in step (1) is 1-10% of the total mass of the reactants;
(3) preheating glycerin, fatty acids and water in the feed chute to 55-75° C., then charged into the reactor body to initiate a synthesis reaction; a blowing mechanism is actuated and the flow rate of an inert gas is controlled at 0.7-5.7 cm/s, so that the inert gas is continuously blown into the reactor body via a sieve plate, forming boiling bubbles;
(4) turning off the hot bath mechanism and the blowing mechanism after the synthesis reaction is carried out for 15-90 min, stopping the heating and the inert gas circulation, actuating a compacting mechanism, and standing and layering the reaction mixture, thus obtaining an upper layer, which is a crude glycerin layer, and a lower layer, which is a glycerol layer; the crude glycerin layer is removed off the free fatty acids via a first-stage molecular distillation, then sent into a second-stage molecular distillation, thus obtaining a distillate and a distillation residue; wherein the distillate is high purity diglyceride, and the distillation residue is monoglyceride;
wherein the bubble column reactor in step (1) comprises a reactor body, a bearing mechanism, a sieve plate, a compacting mechanism, a blowing mechanism, a hot bath mechanism, a feed chute, and a connecting cylinder, wherein the reactor body, the bearing mechanism and the connecting cylinder are connected sequentially from top to bottom; the hot bath mechanism, the reactor body, and feed chute are sequentially connected, and formed a hot bath circulation; the reactor body is communicated with the connecting cylinder, the connecting cylinder is connected to the blowing mechanism, the sieve plate is placed on the upper end of the connecting cylinder, the compacting mechanism is mounted on the connecting cylinder, the upper end of the compacting mechanism is inserted into the connecting cylinder, and the upper end of the compacting mechanism is abutted against the sieve plate;
wherein the compacting mechanism comprises a floating joint, a cylinder, a compacting head, wherein the piston rod of the cylinder is connected to the compacting head via the floating joint, the compacting head is abutted against the sieve plate; the upper end of the compacting head is provided with a first upper cavity, the first upper cavity is communicated with the internal cavity of the reactor body via the sieve plate, the bottom surface of the first upper cavity is arranged in an inclined mode; the lower end of the compacting head is provided with a first lower cavity, the floating joint is connected to the first lower cavity; the side wall of the upper end of the compacting head is provided with a first through hole, the first through hole is communicated with the first upper cavity and the internal cavity of the connecting cylinder; and
wherein the internal cavity of the connecting cylinder is provided with flow-guiding plate, the internal cavity of the connecting cylinder is divided into a second upper cavity and the second upper cavity by the flow-guiding plate, the second upper cavity is communicated with the internal cavity of the reactor body, the flow-guiding plate is arranged in an inclined mode, the middle of the flow-guiding plate is provided with a second through hole through which the piston rod of the cylinder passes, the floating joint is sleeved with a sealing sleeve, the sealing sleeve is closely connected to the second through hole; the connecting cylinder is provided with a gas ventilating hole and a liquid collecting hole, both the gas ventilating hole and the liquid collecting hole are communicated with the second upper cavity, the gas ventilating hole is connected to the blowing mechanism; the axis of the liquid collecting hole is arranged in parallel with the flow-guiding plate, and the lower end of the flow-guiding plate is at the same height as that of the lower edge of the liquid collecting hole.
US Pat. No. 10,137,221

HEMOSTATIC MIXTURE OF CELLULOSE-BASED SHORT AND LONG FIBERS

Omrix Biopharmaceuticals ...

1. Hemostatic fibers and/or aggregates composition comprising long and fine cellulose-based fibers comprised of oxidized cellulose and/or oxidized regenerated cellulose, wherein the concentration of the long fibers is in the range of 5%-25% w/w and the concentration of the fine fibers is in the range of 95%-75% w/w of the entire weight composition, wherein the size distribution of the long fibers is: D90 of more than 177 ?m and D50 of more than 95 ?m, and wherein the size distribution of the fine fibers is: D90 of less than 177 ?m, and D50 of less than 95 ?m.
US Pat. No. 10,137,733

PNEUMATIC TIRE

SUMITOMO RUBBER INDUSTRIE...

1. A pneumatic tire, comprising a tread formed from a rubber composition,the rubber composition comprising:
an oil-extended polybutadiene rubber having a cis content of 95 mol % or more, a vinyl content of 1 mol % or less, and a weight average molecular weight of 530,000 or more;
at least one of an isoprene-based diene rubber or a styrene-butadiene rubber;
a carbon black having a nitrogen adsorption specific surface area of 110 to 200 m2/g; and
stearic acid,
the oil-extended polybutadiene rubber being synthesized using a rare earth catalyst,
the rubber composition comprising, based on 100% by mass of the total rubber solids, 8% to 65% by mass of a polybutadiene rubber component contained in the oil-extended polybutadiene rubber and 20% to 85% by mass of the at least one of an isoprene-based diene rubber or a styrene-butadiene rubber,
the rubber composition comprising, relative to 100 parts by mass of the total rubber solids, 20 to 100 parts by mass of the carbon black and 1.5 to 2.99 parts by mass of the stearic acid,
the rubber composition having an amount of process oil of 9 parts by mass or less relative to 100 parts by mass of the total rubber solids.
US Pat. No. 10,138,502

METHOD FOR PRODUCING OIL CONTAINING POLYUNSATURATED FATTY ACID USING LIPASE

NIPPON SUISAN KAISHA, LTD...

1. A method for lowering saturated fatty acid content in a glyceride containing a polyunsaturated fatty acid, the method comprising:concentrating the polyunsaturated fatty acid using a lipase having low reactivity for the polyunsaturated fatty acid to hydrolyze the glyceride containing the polyunsaturated fatty acid, wherein the glyceride containing the polyunsaturated fatty acid is a marine animal oil glyceride or a microorganism oil glyceride;
wherein the polyunsaturated fatty acid is a fatty acid having at least 20 carbon atoms and having at least 3 double bonds,
wherein the hydrolysis by the lipase is performed in the presence of 10 to 200 weight percent of water based on a total weight of the glyceride containing the polyunsaturated fatty acid, and at a temperature from 10° C. to 20° C.,
wherein the lipase is derived from a microorganism selected from the group consisting of Candida cylindracea and Alcaligenes sp.; and
wherein the saturated fatty acid content in the resulting glyceride is less than the saturated fatty acid content in the glyceride prior to the concentrating.
US Pat. No. 10,137,222

FIBRIN COMPOSITION, METHOD AND WOUND ARTICLES

3M INNOVATIVE PROPERTIES ...

1. A method of forming a fibrin hydrogel composition comprisingforming an aqueous solution comprising fibrinogen, fibrin-forming enzyme, and a fibrin hydrogel forming salt; wherein the fibrin hydrogel forming salt has a concentration greater than or equal to the threshold concentration to form a fibrin hydrogel;
reducing the salt concentration below the threshold concentration to form a fibrin hydrogel.
US Pat. No. 10,138,504

PRODUCTION OF MALONYL-COA DERIVED PRODUCTS VIA ANAEROBIC PATHWAYS

Lallemand Hungary Liquidi...

1. A recombinant yeast microorganism comprisingone or more engineered metabolic pathways to convert a carbohydrate source to a malonyl-CoA derived product,
wherein the one or more engineered metabolic pathways comprises
(a) the conversion of phosphoenolpyruvate to oxaloacetate by a phosphoenolpyruvate carboxykinase and
(b) the conversion of oxaloacetate and acetyl-CoA to malonyl-CoA and pyruvate by a heterologous transcarboxylase Enzyme Commission Number 2.1.3.1;
wherein the one or more engineered metabolic pathways further comprises downregulation or deletion of native pyruvate decarboxylase, and wherein the one or more engineered metabolic pathway further comprises heterologous pyruvate formate lyase.
US Pat. No. 10,137,224

ALLOGENEIC MICROVASCULAR TISSUE FOR SOFT TISSUE TREATMENTS

MICROVASCULAR TISSUES, IN...

1. A processed microvascular tissue comprising:a dried microvascular tissue, wherein the microvascular tissue comprises dissociated, and uncultured stem or progenitor cells having intact cell membranes, wherein the viability of the uncultured stem or progenitor cells in the processed microvascular tissue is less than 30%, and wherein the processed microvascular tissue has tissue healing activity.
US Pat. No. 10,138,505

PROCESS FOR THE PRODUCTION OF ORGANIC COMPOUNDS FROM PLANT SPECIES

Novamont S.p.A., Novara ...

1. A process for the production of fermentable C5-C6 sugars from oleaginous herbaceous plants belonging to the Cardueae tribe, comprising the steps of:a) mechanically separating the seeds from the above-ground lignocellulose biomass of the oleaginous herbaceous plants and comminuting said lignocellulose biomass;
b) bringing the comminuted lignocellulose biomass into contact with a basic aqueous solution containing 5 vol. % or less of an organic solvent in order to prepare an aqueous paste containing the comminuted lignocellulose biomass in an amount of 10 to 50% by weight, at a temperature of between 10 and 95° C. and for a time of between 1 minute and 24 hours;
c) separating the paste into a first solid fraction and a first liquid fraction;
d) subjecting the solid fraction to enzyme hydrolysis of the hemicellulose and cellulose contained therein.
US Pat. No. 10,137,225

CRYSTALLINE COATING AND RELEASE OF BIOACTIVE AGENTS

Yissum Research Developme...

1. A process of depositing at least a first layer of a first therapeutically active agent onto at least a continuous portion of a surface of an object, wherein at least 50 weight percents of said first layer is said first therapeutically active agent in a crystalline form, the process comprising:seeding said surface of said object with crystals of said first therapeutically active agent, so as to obtain a seeded surface comprising said crystals; and
contacting said seeded surface with a solution containing said first therapeutically active agent for at least 5 minutes, so as to effect precipitation of said first therapeutically active agent onto said seeded surface in a crystalline form, thereby forming said crystalline form of said first therapeutically active agent deposited on at least said portion of said surface,
wherein said surface is not cooled to a temperature below a temperature of said solution.
US Pat. No. 10,138,506

ENZYMATIC PRODUCTION OF D-TAGATOSE

BONUMOSE LLC, Charlottes...

1. An enzymatic process for preparing tagatose from a starch derivative, the process comprising the steps of:(i) converting a saccharide to glucose 1-phosphate (G1P) using alpha glucan phosphorylase (?GP), wherein the saccharide is selected from one or more derivatives of starch;
(ii) converting G1P to glucose 6-phosphate (G6P) using a phosphoglucomutase (PGM);
(iii) converting G6P to fructose 6-phosphate (F6P) using a phosphoglucoisomerase (PGI);
(iv) converting fructose 6-phosphate (F6P) to tagatose 6-phosphate (T6P) catalyzed by a fructose 6-phosphate epimerase (F6PE); and
(v) converting the T6P produced to tagatose catalyzed by a tagatose 6-phosphate phosphatase (T6PP)
wherein steps (i)-(v) are conducted in a single reaction vessel.
US Pat. No. 10,138,507

MANUFACTURING METHODS FOR PRODUCTION OF RNA TRANSCRIPTS

ModernaTX, Inc., Cambrid...

1. A method for producing a purified composition comprising a capped RNA transcript for a gene of interest, the method comprising:(a) providing a sample comprising a linear, non-amplified DNA template, the DNA template comprising an RNA polymerase promoter sequence operatively linked to a target sequence coding for the gene of interest, a poly A tail sequence of 60-160 nucleotides, an endonuclease recognition site sequence immediately downstream of the poly A tail sequence, and a 5? untranslated region (UTR) and/or a 3? UTR;
(b) contacting the sample with a RNA polymerase and ribonucleotides under conditions sufficient for vitro transcription to produce a first composition comprising an uncapped RNA transcript wherein at least 80% of the RNA transcript is full-length uncapped RNA transcript;
(c) purifying the uncapped RNA transcript using oligo dT affinity purification;
(d) capping the uncapped RNA transcript by contacting the RNA transcript with quanlyltransferase, s-adenosyl-L-methionine, guanosine triphosphate, and 2?-O-methyltransferase to produce a second composition comprising a capped RNA transcript;
(e) purifying the capped RNA transcript from the second composition by anion exchange chromatography; and
(f) filtering the capped RNA transcript by ultrafiltration or tangential flow filtration, thereby producing the purified composition comprising a capped RNA transcript,wherein the method does not comprise treating the composition with DNase.
US Pat. No. 10,138,509

METHOD FOR GENERATING A THREE-DIMENSIONAL NUCLEIC ACID CONTAINING MATRIX

President and Fellows of ...

1. A method of identifying nucleic acids within a cell, comprising:contacting a plurality of nucleic acids having a relative three-dimensional spatial relationship within the cell with a matrix-forming material in a manner to substantially retain the relative three-dimensional spatial relationship;
using the matrix-forming material to form a three-dimensional polymerized matrix including the nucleic acids of the plurality of nucleic acids covalently bound to the three-dimensional polymerized matrix; and
detecting signals from the nucleic acids or derivatives thereof, thereby identifying the nucleic acids.
US Pat. No. 10,138,510

DUAL LABELING METHODS FOR MEASURING CELLULAR PROLIFERATION

LIFE TECHNOLOGIES CORPORA...

1. A method for measuring a change in cellular DNA synthesis:a) incubating a sample with an effective amount of a first nucleoside or nucleotide analog comprising an ethynyl group to form a primary incubated sample,
wherein the first nucleoside or nucleotide analog is ethynyl-deoxyuracil (EdU);
b) incubating the primary incubated sample with a second nucleoside or nucleotide analog comprising a halogen moiety to form a secondary incubated sample,
wherein the second nucleoside or nucleotide analog is BrdU, and wherein the first nucleoside or nucleotide analog is not incorporated into a DNA polymer when the second nucleoside or nucleotide analog is present;
c) incubating the secondary incubated sample with a first labeling reagent comprising an azide group that can undergo a [3+2] cycloaddition reaction with the ethynyl group of the first nucleoside or nucleotide analog and a second labeling reagent that is an antibody that binds to the second nucleoside or nucleotide analog to form a labeled sample; and
d) detecting the labeled sample wherein a level of incorporation of the first nucleoside or nucleotide analog is measured and allows establishment of a baseline rate of the cellular DNA synthesis and a level of incorporation of the second nucleoside or nucleotide analog is measured,
wherein a difference between the level of incorporation of the second nucleoside or nucleotide analog relative to the baseline rate indicates a change in cellular DNA synthesis,
with the proviso that there is no wash step prior to adding the second nucleoside or nucleotide analog.
US Pat. No. 10,139,022

HEATABLE PIPE

Evonik Degussa GmbH, Ess...

1. A heatable pipe, comprising:a layer (layer I) of a moulding compound comprising a east 40 wt. % of the following components:
1) 60 to 99 parts by wt. of a partly aromatic copolyamide containing monomer units obtained from
?) 30 to 90 mol % of a combination of hexamethylenediamine and terephthalic acid, and
?) 70 to 10 mol % of a combination of hexamethylenediamine and a linear aliphatic dicarboxylic acid having 8 to 19 carbon atoms;
wherein the mol % values relate to the sum of ?) and ?) and
wherein not more than 20% of the hexamethylenediamine is optionally replaced by the equivalent amount of another diamine and/or
wherein not more than 20% of the terephthalic acid is optionally replaced by the equivalent amount of another aromatic dicarboxylic acid and/or 1,4-cyclohexanedicarboxylic acid and/or
wherein not more than 20% of the repeating units containing hexamethylenediamine and linear aliphatic dicarboxylic acid are optionally replaced by the equivalent amount of units obtained from a lactam/an ?-aminocarboxylic acid having 6 to 12 carbon atoms,
2) 40 to 1 parts by wt. of an olefinic copolymer as impact modifier,
wherein the parts by wt. of 1) and 2) sum to 100; and
a conductor for electrical current which is embedded between an electrically insulating outer layer and an electrically insulating inner layer.
US Pat. No. 10,138,511

ARRAYS OF MICROPARTICLES AND METHODS OF PREPARATION THEREOF

BioArray Solutions Ltd., ...

1. A method of retaining a population of charged beads in recesses in a surface of a semiconductor comprising depositing a first charged polymer on the surface of the semiconductor, said first charged polymer having a charge of opposite sign to the charged beads, depositing the beads onto the surface of the semiconductor, and depositing a second charged polymer on the surface of the semiconductor, said second charged polymer having a charge of opposite sign to the first charged polymer.
US Pat. No. 10,138,512

NUCLEIC ACID PROCESSING OF A NUCLEIC ACID FRAGMENT WITH A TRIAZOLE LINKAGE

ATDBIO LIMITED, Southham...

1. A method of nucleic acid processing comprising:providing an adapted nucleic acid fragment comprising a nucleic acid fragment linked at its 3?-end to a 3?-adapter molecule by a triazole linkage comprising a 1,2,3-triazole group, wherein the 3?-adapter molecule comprises RNA, DNA, a nucleic acid analogue or combinations thereof;
annealing a primer to the adapted nucleic acid fragment, wherein the primer anneals to a region of the 3?-adapter molecule; and
processing the adapted nucleic acid fragment by transcribing at least a portion of the adapted nucleic acid fragment with reverse transcriptase, wherein said portion of the adapted nucleic acid fragment transcribed with reverse transcriptase comprises said triazole linkage.
US Pat. No. 10,138,513

METHOD AND DEVICE FOR AMPLIFYING AND DETECTING GENE USING GRAPHENE HEATER

ELECTRONICS AND TELECOMMU...

1. A gene amplifying and detecting device, comprising:a gene amplifying chip including a chamber formed therein, the gene amplifying chip having a first sidewall and a second sidewall opposite to the first sidewall;
a reaction solution in the chamber and including a fluorescent material;
a light source adjacent to the first sidewall of the gene amplifying chip;
a light detector located adjacent to the second sidewall of the gene amplifying chip; and
a first graphene heater adjacent to the first sidewall of the gene amplifying chip so as to heat the reaction solution to cause a circulating flow of the reaction solution by convection,
wherein the first graphene heater is positioned between the light source and the chamber to transmit light generated from the light source into the chamber.
US Pat. No. 10,137,234

METHOD FOR STERILIZING BLOOD PURIFIER AND BLOOD PURIFIER PACKAGE

NIPRO CORPORATION, Osaka...

1. A method for sterilizing a blood purifier comprising substantially dried selectively permeable separation membranes as a main component, by exposing said blood purifier to a radioactive ray and/or an electron ray, characterized in that said selectively permeable separation membranes comprise a hydrophobic polymer containing a hydrophilic polymer, said hydrophobic polymer comprises a polysulfone-based polymer, and said blood purifier is sealed in a packaging bag, together with an oxygen scavenger and a humectant or together with an oxygen scavenger capable of releasing a moisture, and is then sterilized in such a sealed state, wherein the relative humidity (RH) in the inner atmosphere of the packaging bag at room temperature is not lower than 50% RH.
US Pat. No. 10,138,516

METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI

Natera, Inc., San Carlos...

1. A method of amplifying target loci of DNA molecules in a nucleic acid sample, the method comprising:(a) contacting the sample and a library of at least 1,000 non-immobilized, non-identical primers that hybridize to at least 1,000 non-identical target loci to produce a reaction mixture in which the concentration of each primer is less than 20 nM; wherein the average length of the DNA molecules is less than 200 base pairs; and wherein a range of melting temperatures of the at least 1000 non-identical primers is less than 10° C.;
(b) subjecting the reaction mixture to PCR conditions to produce amplified products comprising target amplicons; wherein a length of an annealing step of the PCR conditions is greater than 10 minutes; wherein the length of the target amplicons is less than 100 nucleotides; wherein at least 1,000 different target human loci are amplified, and wherein at least 50% of the amplified products comprise target loci.
US Pat. No. 10,137,236

SELF-REGULATING DEVICE FOR MODULATING INFLAMMATION

1. A method of inhibiting tumor necrosis factor-alpha (TNF-?) comprising, providing blood of a patient to an extracorporeal bioreactor, wherein the extracorporeal bioreactor comprises: a compartment comprising cells and a selectively permeable membrane in contact with the cells that does not permit passage of the cells and which permits passage of TNF-? in the blood of the patient, wherein the cells comprise a chimeric gene comprising a response element operably linked to a sequence encoding a soluble TNF-? receptor (sTNFR), in which the response element causes expression of the sTNFR when the cells are contacted with the TNF-? in the blood of the patient; contacting the blood with the selectively permeable membrane, such that the TNF-? in the blood passes through the selectively permeable membrane and sTNFR produced by the cells passes into the blood; and returning the blood to the patient, thereby inhibiting TNF-?.
US Pat. No. 10,138,517

MANIPULATION OF MICROPARTICLES IN MICROFLUIDIC SYSTEMS

CALIPER LIFE SCIENCES, IN...

1. A method of modifying flow in a microchannel, the method comprising:flowing a first particle set into the microchannel;
performing a first assay in the microchannel;
moving the first particle set within the microchannel and flowing a second particle set stacked against the first particle set into the microchannel, thereby altering the hydrodynamic resistance in the microchannel; and,
performing a second assay in the microchannel.
US Pat. No. 10,138,518

ANNEALING CONTROL PRIMER AND ITS USES

SEEGENE, INC., Seoul (KR...

1. An annealing control primer for improving annealing specificity in nucleic acid amplification, having the formula:5?-Xp—Yq—Zr-3?
wherein Xp represents a 5?-end portion consisting of a pre-selected arbitrary nucleotide sequence substantially not complementary to any site on a template nucleic acid;
wherein Yq represents a regulator portion consisting of 5-15 contiguous universal bases;
wherein Zr represents a 3?-end portion having a hybridizing nucleotide sequence substantially complementary to a site on the template nucleic acid to hybridize therewith;
wherein p, q and r represent the number of nucleotides;
wherein X, Y and Z is deoxyribonucleotide or ribonucleotide;
wherein the base of the deoxyribonucleotide of X is selected from the group consisting of adenine(A), cytosine(C), guanine(G) and thymine(T);
wherein the regulator portion has the lowest Tm in the three portions of the primer, whereby the regulator portion is capable of regulating an annealing portion of the primer in association with annealing temperatures; and
wherein the 5?-end portion is not involved in annealing to the template nucleic acid under conditions that the 3?-end portion anneals to the site on the template nucleic acid such that the 5?-end portion remains unhybridized with the template nucleic acid.
US Pat. No. 10,138,262

REACTIVE MULTI-FUNCTIONAL ADDITIVES FOR COATINGS COMPOSITIONS

Dow Global Technologies L...

1. An acrylic coating composition comprising:(I) from 15 to 45 wt % of a dispersed polymer comprising from 80 to 100 wt % acrylic monomers;
(II) from 15 to 35 wt % titanium dioxide;
(III) from 30 to 70 wt % water; and
(IV) from 1 to 5 wt % of a reactive multi-functional additive, said reactive multi-functional additive comprising:
(i) a multi-functional additive comprising:
(a) from 30 to 50 wt % of a saccharide component having formula (S)m{(CH2CH(R)O)nR1}k, where R1 is hydrogen or —C(O)CH2C(O)CH3, and wherein each group of formula (CH2CH(R)O)nR1 is bonded to an oxygen atom; and
(b) from 50 to 70 wt % of a non-saccharide component having formula P{(CH2CH(R2)O)OR3}p, where R3 is hydrogen or —C(O)CH2C(O)CH3, and wherein each group of formula (CH2CH(R2)O)nR3 is bonded to an oxygen atom;
wherein (CH2CH(R)O)n and (CH2CH(R2)O)n collectively comprise from 30 to 70 wt % of said multi-functional additive; and
wherein n is from 0.5 to 3 and represents a number average; o is from 0.5 to 3 and represents a number average; k is from 4 to 8 and represents a number average; and p is from 2 to 3 and represents a number average; and wherein (S)m is a sucrose unit and R is methyl; and
wherein P is a glycerol unit and R2 is methyl; and
(ii) ammonia or an aliphatic amine having a molecular weight from 60 to 500, wherein the ratio of the number of equivalents of amine to the number of equivalents of acetoacetyl groups is from 0.8:1 to 2:1.
US Pat. No. 10,138,520

DIAGNOSTIC MIRNA MARKERS FOR ALZHEIMER

SIEMENS AKTIENGESELLSCHAF...

1. A method of treating Alzheimer's Disease in a patient in need thereof, said method comprisingadministering an anti-Alzheimer's Disease therapy to the patient, wherein a blood sample from the patient exhibits an expression level value of at least one miRNA selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 7, SEQ ID NO 56, SEQ ID NO 58, SEQ ID NO 59, SEQ ID NO 64, SEQ ID NO 65, SEQ ID NO 66, SEQ ID NO 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 73, SEQ ID NO 78, SEQ ID NO 85, SEQ ID NO 142 and SEQ ID NO 236 compared to a reference expression level value.
US Pat. No. 10,138,264

RECOMBINED MOLECULES AND PREPARATION THEREOF

VALENT TECHNOLOGIES LLC, ...

1. A method for preparation of a recombined molecule from vancomycin comprising the steps of:(a) cleavage of vancomycin with a protease;
(b) splitting the cleaved vancomycin molecules into two separate pools: a first pool and a second pool;
(c) acylating the cleaved vancomycin molecules of the first pool with an acylating agent to acylate all alcohols and amino groups of the cleaved vancomycin molecules of the first pool;
(d) methylating the cleaved vancomycin molecules of the second pool with a methylating agent to methylate all carboxylic acid moieties of the cleaved vancomycin molecules of the second pool;
(e) recombining the acylated cleaved vancomycin molecules of the first pool and the methylated cleaved vancomycin molecules of the second pool by forming peptide bonds with a peptide bond forming agent to afford a recombined molecule from vancomycin comprising acetyl protecting groups and methyl protecting groups; and
(f) removing all acetyl protecting groups and all methyl protecting groups present in the recombined molecule from vancomycin in step (e) by base hydrolysis to produce a recombined molecule from vancomycin.
US Pat. No. 10,138,521

TREATMENT AND DIAGNOSIS OF EPIGENETIC DISORDERS AND CONDITIONS

Murdoch Childrens Researc...

1. A method of detecting methylation in Fragile X-related Epigenetic Element 2(E) (FREE2(E)) in genomic DNA of a human subject, the method comprising:(a) obtaining isolated genomic DNA from the human subject,
(b) amplifying wholly or partially
FREE2(E) consisting of the nucleotide sequence of SEQ ID NO:49 or a modified SEQ ID NO:49 in which methylated cytosine(s) in SEQ ID NO:49 are converted to uracil(s) using a first primer complementary to a first region of SEQ ID NO:49 or to the modified SEQ ID NO:49 sequence in which methylated cytosine(s) have been converted to uracil(s) and a second primer complementary to a second region of SEQ ID NO:49 or to the modified SEQ ID NO:49 sequence in which methylated cytosine(s) have been converted to uracil(s), wherein the second primer is non-overlapping with the first primer; and
(c) detecting methylation in the wholly or partially amplified FREE2(E).
US Pat. No. 10,138,522

IDENTIFICATION OF CATTLE AT RISK OF HIGH ALTITUDE PULMONARY HYPERTENSION

VANDERBILT UNIVERSITY, N...

7. A method of breeding cattle, comprising,a) subjecting a nucleic acid-containing sample from a head of cattle to nucleic acid sequence analysis;
b) analyzing the nucleotide present at positions 1816 and/or 1828 in exon 12 of the bovine EPAS1 gene;
c) detecting a G allele at position 1816 in exon 12 of the bovine EPAS1 gene and/or a G allele present at position 1828 in exon 12 of the bovine EPAS1 gene; and
d) breeding the head of cattle with a G allele at position 1816 in exon 12 of the bovine EPAS1 gene and/or a G allele present at position 1828 in exon 12 of the bovine EPAS1 gene.
US Pat. No. 10,138,266

METHOD OF CUTTING OUT RNA OLIGONUCLEOTIDE

Nitto Denko Corporation, ...

1. A method of cutting out an RNA oligonucleotide chemically synthesized on a universal support from the support, comprisinga step of bringing the support carrying the RNA oligonucleotide in contact with an aqueous solution containing alkylamine and 10-60 mM monovalent inorganic salt.
US Pat. No. 10,138,523

CANCER BIOMARKER AND DIAGNOSTIC

1. A method for monitoring colorectal cancer in a subject, wherein the method comprises:(i) measuring the level of ATP11B and S100A11 gene expression or the quantity of protein or peptides resulting from ATP11B and S100A11 gene translation in samples from the subject from two or more successive time points;
(ii) comparing the level or quantity of both markers between the samples as measured in (i);
(iii) finding a deviation of at least about 40% (about 1.4-fold or more)_or no deviation of the quantity of both markers between the samples as compared in (ii); and
(iv) attributing the finding of deviation or no deviation to a change in the colorectal cancer in the subject between the two or more successive time points.
US Pat. No. 10,138,524

SYNTHETIC NUCLEIC ACID CONTROL MOLECULES

EXACT SCIENCES DEVELOPMEN...

1. A run control composition for a diagnostic assay, wherein the diagnostic assay is configured to provide a diagnostic result by measuring a ratio of an amount of a gene in a sample from a human subject that is methylated in a methylation assay footprint nucleotide sequence in the gene to an amount of the gene in the sample that is not methylated in said methylation assay footprint nucleotide sequence, wherein a ratio in a sample above a cutoff value measured by the diagnostic assay is indicative of a disease state in the human subject, the run control composition comprising:(a) a first synthetic DNA fragment comprising the methylation footprint nucleotide sequence of said human gene, the methylation footprint nucleotide sequence in said first synthetic DNA fragment comprising a pattern of cytosines, wherein each of the cytosines within the methylation footprint nucleotide sequence comprises a 5-methyl;
(b) a second synthetic DNA fragment comprising the methylation footprint nucleotide sequence of said human gene, the methylation footprint nucleotide sequence in said second synthetic DNA fragment comprising the same number and pattern of cytosines as the methylation footprint nucleotide sequence in the first synthetic DNA fragment, wherein none of the cytosines within the methylation footprint nucleotide sequence in the second synthetic DNA fragment comprises a 5-methyl, and
(c) fish DNA;
wherein a ratio of the number of copies of the first synthetic DNA fragment to the number of copies of the second synthetic DNA fragment in the run control composition is above said cutoff value.
US Pat. No. 10,138,268

PEPTIDE FRAGMENT CONDENSATION AND CYCLISATION USING A SUBTILISIN VARIANT WITH IMPROVED SYNTHESIS OVER HYDROLYSIS RATIO

ENZYPEP B.V., Geleen (NL...

1. A method for enzymatically synthesizing an (oligo)peptide, comprising:coupling (a) an (oligo)peptide C-terminal ester or thioester and (b) an (oligo)peptide nucleophile having an N-terminally unprotected amine,
wherein the coupling is carried out in a fluid comprising water, and
wherein the coupling is catalyzed by a subtilisin BPN? variant or mutant, said variant or mutant comprising mutations, said mutations comprising:
a deletion of the calcium binding domain corresponding to amino acid corresponding to positions 75-83; and
a mutation at the amino acid position corresponding to S221, the mutation corresponding to S221C or S221selenocysteine;
wherein the amino acid positions are defined based upon the numbering of the amino acid sequence of SEQ ID NO:2, and wherein the subtilisin BPN? variant or mutant has enzymatic activity.
US Pat. No. 10,138,525

COMPOSITIONS AND METHODS TO DETECT ATOPOBIUM VAGINAE NUCLEIC ACID

GEN-PROBE INCORPORATED, ...

1. A method for detecting in a sample a 16S rRNA of A. vaginae or a gene encoding a 16S rRNA of A. vaginae, comprising the steps of:a. providing a sample, wherein said sample is suspected of containing an Atopobium vaginae bacterium;
b. contacting said sample with at least two amplification oligomers, each being from 15 to 25 nucleotides in length and configured to generate from a 16S rRNA of A. vaginae or a gene encoding a 16S rRNA of A. vaginae, an amplicon comprising a nucleotide sequence that is SEQ ID NO:43, wherein said at least two amplification oligomers specifically hybridize to A. vaginae target nucleic acid in the presence of one or more of G. vaginalis, Prevotella sp, anaerobic gram positive cocci, Mobiluncus sp, Mycoplasma hominis, Eggerthella hongkongensis, Megasphaera sp, and/or Leptotrichia sanguinegens;
c. performing an in vitro nucleic acid amplification reaction wherein any target nucleic acid present in said sample is used as a template for generating an amplification product; and
d. performing a detection reaction to determine the presence or absence of the amplification product.
US Pat. No. 10,138,526

MOLECULAR MARKERS ASSOCIATED WITH STEM CANKER RESISTANCE IN SOYBEAN

Monsanto Technology LLC, ...

1. A method of producing a population of soybean plants that comprises a genotype associated with a stem canker resistance phenotype, the method comprising:(i) genotyping a first population of soybean plants, wherein the first population contains at least one allele associated with the stem canker resistance phenotype, wherein the allele is located in at least one stem canker resistance marker locus, wherein the stem canker resistance marker locus is in a linkage group Dlb genomic region , and wherein said genomic region is flanked by and including:
a) loci NGMAX008369670 and NGMAX008369689;
b) loci NGMAX008369675 and NGMAX008369689;
c) loci NGMAX008369673 and NGMAX008369689;
d) loci NGMAX008369676 and NGMAX008369689;
e) loci NGMAX008369683 and NGMAX008369689;
f) loci NGMAX008369675 and NGMAX008369686;
g) loci NGMAX008369673 and NGMAX008369686;
h) loci NGMAX008369676 and NGMAX008369686; or,
i) loci NGMAX008369683 and NGMAX008369686,
(ii) selecting from said first population of soybean plants based upon said genotyping one or more soybean plants comprising the at least one allele associated with a stem canker resistance phenotype; and
(iii) producing offspring from the one or more selected soybean plants of the first population of soybean plants by crossing the selected soybean plant with another soybean plant,
thereby producing a second population of soybean plants comprising a genotype associated with a stem canker resistant phenotype.
US Pat. No. 10,138,527

METHOD FOR MONITORING DIFFERENTIATION INTO CARDIAC MUSCLE CELLS

OLYMPUS CORPORATION, Tok...

1. A method for monitoring differentiation into cardiac muscle cells comprising:introducing, into cells, a reporter gene of luminescent protein configured to vary in luminescence intensity according to an expression of a myocardial differentiation marker gene, wherein the reporter gene is a cTnT gene expression specific luminescent vector, wherein the cells are stem cells or cardiac progenitor cells;
keeping, in an alive state, the cells into which the reporter gene of luminescent protein were introduced;
acquiring a luminescence image as a still image by imaging light emitted from the cells in a light shielding state;
acquiring sequential images with illuminating the cells, the step of acquiring the sequential images comprising acquiring a bright-field image of the cells;
associating biological information obtained from the sequential images with biological information obtained from the still image;
conducting a motion analysis based on the bright-field image, wherein the motion analysis is conducted by use of an image correlation method;
analyzing beating of the cells by the motion analysis;
analyzing expression of the myocardial differentiation marker gene based on the luminescence image; and
assessing a relationship between the beating and the expression.
US Pat. No. 10,138,271

NATIVE AND AGONIST CTL EPITOPES OF THE MUC1 TUMOR ANTIGEN

The United States of Amer...

1. A method of enhancing an immune response against a MUC1-expressing cancer in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising(i) a poxvirus vector comprising a nucleic acid encoding a peptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 29, and SEQ ID NO: 32, or
(ii) a liposome comprising a peptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 29, and SEQ ID NO: 32,
wherein the immune response in the subject is enhanced.
US Pat. No. 10,138,016

COATED BOX WITH ANTI-GREASY FINGERPRINT COATING

FC Meyer Packaging LLC, ...

1. A container, comprising:a paperboard having creases that fold the paperboard into a box shape that has exterior facing surfaces that face away from each other and interior facing surfaces that face each other;
a water-based barrier coating on portions of the exterior facing surfaces of the paperboard to coat the portions and that is configured to prevent staining from grease and water of the portions of the exterior facing surfaces of the paperboard that are coated, the water-based barrier coating having 35% to 45% solid suspension and being configured to exhibit a hydrophobic effect to deposits of water and oil, the exterior facing surfaces also having uncoated portions that are uncoated and thereby lack the water-based barrier coating, the water-based barrier coating including a primer coat layer applied on the paperboard with the paperboard remaining open to absorb moisture even though the primer coat is applied on the paperboard, an overcoat layer on the primer coat layer and having a higher volume of a same coating material than that of the primer coat layer, the primer coat and the overcoat together providing a surface tension necessary to seal the paperboard against absorbing fluid and resist staining from greasy fingerprints; and
a water-based adhesive adhering the uncoated portions of the exterior facing surfaces to portions of the interior facing surfaces that are in alignment therewith.
US Pat. No. 10,138,272

MATRIPTASE AND U-PLASMINOGEN ACTIVATOR SUBSTRATES AND OTHER CLEAVABLE MOIETIES AND METHODS OF USE THEREOF

CytomX Therapeutics, Inc....

1. An isolated polypeptide comprising a cleavable moiety (CM), wherein the CM comprises the amino acid sequence of SEQ ID NO: 363, wherein the CM is a substrate for a protease, wherein the isolated polypeptide comprises at least one moiety (M) selected from the group consisting of a moiety that is located amino (N) terminally to the CM (MN), a moiety that is located carboxyl (C) terminally to the CM (MC), and combinations thereof, and wherein the MN or MC is selected from the group consisting of an antibody or antigen binding fragment thereof (AB), a therapeutic agent, an antineoplastic agent, a toxic agent, a drug, and a detectable label.
US Pat. No. 10,138,529

METHOD FOR FABRICATION OF A TIMEPIECE BALANCE SPRING

Nivarox-FAR S.A., Le Loc...

1. A method for fabricating an antiferromagnetic and temperature compensated timepiece balance spring, the method comprising:(10) selecting an amagnetic compensating alloy comprising, by mass percent, between and including the range limit values:
from 21.0% to 25.0% of manganese,
from 9.0% to 13.0% of nickel,
from 6.0% to 15.0% of chromium,
from 0.2% to 2.0% of beryllium,
the remainder iron,
the total of the nickel and the manganese being higher than or equal to 33.0%;
(11) working said alloy to obtain a blank;
(12) shaping said blank by casting, forging, wire drawing, rolling, drawing, or any combination thereof, to obtain a blank of spring wire;
(13) winding said wire on a winder to obtain a spiral spring; and
(14) subjecting said spiral spring to at least a heat setting treatment, by annealing at a temperature comprised between 540° C. and 650° C., for a duration of 30 to 200 minutes, to obtain a balance spring.
US Pat. No. 10,141,607

NONAQUEOUS ELECTROLYTE SECONDARY BATTERY

GS Yuasa International Lt...

1. A nonaqueous electrolyte secondary battery comprising a nonaqueous electrolyte,wherein the nonaqueous electrolyte contains 2-fluorotoluene and lithium difluorophosphate,
the content of the 2-fluorotoluene is 4 mass % or more and 8 mass % or less per the nonaqueous electrolyte, and
the content of the lithium difluorophosphate is 1 mass % or more and 6 mass % or less per the nonaqueous electrolyte.
US Pat. No. 10,138,273

PEPTIDE LIGANDS FOR HEPATIC STELLATE CELLS

The Curators of the Unive...

1. A composition comprising:a polypeptide comprising an amino acid sequence having the amino acid sequence of SEQ ID NO: 6, wherein the polypeptide binds to at least a portion of an insulin-like growth factor 2 receptor (IGF2R) extracellular domain; and
at least one of an anti-fibrotic agent, an anti-cancer agent, or a proapoptotic agent.
US Pat. No. 10,138,276

INHIBITION OF TCR SIGNALING WITH PEPTIDE VARIANTS

SIGNABLOK, Inc., Shrewsb...

1. A composition, the composition comprising a peptide consisting of no more than 25 amino acids according to formulaR1-Y1-Y2-Y3-Y4-Y5-Y6-Y7-Y8-Y9-Y10-Y11-R2,wherein:R1 is selected from the group consisting of N-terminal sugar conjugate and N-terminal lipid conjugate;
Y1 is selected from the group consisting of Arg, Arg-Arg, Arg-Arg-Arg and Arg-Arg-Arg-Arg (SEQ ID NO: 82);
Y2 is selected from the group consisting of Lys, Lys-Lys, Lys-Lys-Lys and Lys-Lys-Lys-Lys (SEQ ID NO: 83);
Y3 is selected from the group consisting of A1-A2-A3, A*1-A*2-A*3-A*4 and A**1-A**2-A**3-A**4, wherein:
A1 is absent or is selected from the group consisting of Val, Ile, Leu and a two amino acid peptide, said peptide consisting of Val, Ile and Leu in any combination;
A2 is absent or is selected from the group consisting of Gly and Met;
A3 is absent or is selected from the group consisting of Phe, Leu, Ile and Tyr;
A*1 is absent or is selected from the group consisting of Arg, Gly, Leu and Ile;
A*2 is absent or is selected from the group consisting of Asn, Gln and Ala;
A*3 is absent or is selected from the group consisting of Ile, Leu and Ser;
A*4 is absent or is selected from the group consisting of Val, Asn and Gly;
A**1 is absent or is selected from the group consisting of Ala, Pro, Cys, Thr, Asn, Met, Glu and a two amino acid peptide, said peptide consisting of Ala, Pro, Cys, Thr, Asn, Met and Glu in any combination;
A**2 is absent or is selected from the group consisting of Thr, Ser, Gly, Ala, Tyr, Pro, Ile, a two amino acid peptide and a three amino acid peptide, said peptide consisting of Thr, Ser, Gly, Ala, Tyr, Pro and Ile in any combination;
A**3 is absent or is selected from the group consisting of Gly, Met, Cys, Pro, Leu, Ile, Gln and a two amino acid peptide, said peptide consisting of Gly, Met, Cys, Pro, Leu, Ile and Gln in any combination;
A**4 is absent or is selected from the group consisting of Ala, Thr, Glu, Asn and Ser;
Y4 is a positively charged amino acid selected from the group comprising Arg, Lys and His;
Y5 is selected form the group consisting of C1, C*1 and C**, wherein:
C1 is a four amino acid peptide consisting of Leu, Ile, Thr and Pro in any combination;
C*1 is a three amino acid peptide consisting of Asp, Leu, Ile, Arg, Lys, Ser, Val and Glu in any combination;
C** is an eight amino acid peptide;
Y6 is a positively charged amino acid selected from the group comprising Arg, Lys and His;
Y7 is selected from the group consisting of E1-E2-E3, E*1 and E**1-E**2-E**3, wherein:
E1 is Val or Tyr;
E2 is absent or is selected from the group consisting of Ala and Phe;
E3 is absent or Gly;
E*1 is a three amino acid peptide consisting of Asp, Asn, Leu, Lys, Ile, Val and Glu in any combination;
E**1 is absent or is selected from the group consisting of Gln, Cys, Glu, Trp and Arg;
E**2 is absent or is selected from the group consisting of Leu, Ile, Phe, Gly and Lys;
E**3 is absent or is selected from the group consisting of Gly and Thr;
Y8 is selected form the group consisting of F1-F2, F*1 and F**1, wherein:
F1 is absent or is selected from the group consisting of Gly, Phe, Asn, a two amino acid peptide and a three amino acid peptide, said peptide consisting of Gly, Phe and Asn in any combination;
F2 is absent or is selected from the group consisting of Leu, Phe, Ile, Met, Thr, Gln, a two amino acide peptide, a three amino acide peptide, a four amino acide peptide and a five amino acide peptide, said peptide consisting of Leu, Phe, Ile, Met, Thr and Gln in any combination;
F*1 is a positively charged amino acid selected from the group comprising Arg, Lys and His;
F**1 is absent or is selected from the group consisting of Asn, Leu, Ile, Thr, Phe, Val, a two amino acid peptide, a three amino acid peptide and a four amino acid peptide said peptide consisting of Asn, Leu, Ile, Thr, Phe and Val in any combination;
Y9 is absent or G*1-G*2, wherein:
G*1 is selected from the group consisting of Ile, Leu and Asp;
G*2 is absent or is selected from the group consisting of Asn and Thr;
Y10 is absent or is selected from the group consisting of Arg, Arg-Arg, Arg-Arg-Arg and Arg-Arg-Arg-Arg (SEQ ID NO: 82);
Y11 is absent or is selected from the group consisting of Lys, Lys-Lys, Lys-Lys-Lys and Lys-Lys-Lys-Lys (SEQ ID NO: 83); and
R2 is absent or is C-terminal lipid conjugate.
US Pat. No. 10,138,533

METHOD FOR PRODUCING HIGH-PURITY CALCIUM

1. High-purity calcium having a purity, excluding gas components, Sr, and Ba, of 4N5 or higher and containing silicon as an impurity in an amount of: less than 0.05 ppm, produced by a process comprising the steps of:charging calcium starting material having a purity, excluding the gas components, of 4N or less into a crucible of a sublimation vessel;
performing first sublimation purification by heating at 750° C. to 800° C. so that calcium is sublimated and deposits (evaporates) onto the inner side wall of the sublimation vessel;
recovering the calcium purified by the first sublimation purification;
charging the calcium into a crucible of a sublimation vessel again;
performing second sublimation purification by heating at 750° C. to 800° C. so that the calcium is sublimated and deposits (evaporates) onto the inner side wall of the sublimation vessel; and
recovering the calcium having a purity, excluding gas components, Sr, and Ba, of 4N5 or higher and containing silicon as an impurity in an amount of less than 0.05 ppm.
US Pat. No. 10,138,277

VIRUS-LIKE PARTICLES AND METHODS OF USE

The United States of Amer...

1. An isolated polynucleotide encoding an altered viral protein selected from the group consisting of:a. an alphavirus E2 protein comprising at least one alteration, relative to the wild-type amino acid sequence, at one or more amino acid locations corresponding to at least one amino acid position selected from the group consisting of H170, K200, K233, K234, R251, and H256 of Chikungunya E2 protein; and
b. an alphavirus capsid protein comprising at least one alteration, relative to the wild type sequence, in the Nuclear Localization Signal (NLS);
wherein the altered protein is capable of self-assembling into a virus like particle (VLP); and,
wherein the at least one alteration enhances production of VLPs.
US Pat. No. 10,138,534

NICKEL ALLOY

ROLLS-ROYCE plc, London ...

1. A nickel alloy having the following composition (in atomic percent unless otherwise stated): between 5.75 and 6.75 Al, between 4.5 and 5.8 Ti, between 0.5 and 1.3 Ta, up to 1% Nb, between 13.5% and 16% Cr, between 22and 27% Co, between 0.1 and 0.3% C, between 0.05 and 0.2% B, between 0.02 and 0.07% Zr, up to 1.1% W, between 1.4 and 2.85% Mo, up to 1% Fe, up to 0.7% Mn, up to 1% Si, up to 0.15% Hf, and up to 0.05% Mg; the balance being Ni and incidental impurities.
US Pat. No. 10,138,278

FLUOROGEN ACTIVATING AND SHIFTING TAG (FAST)

CENTRE NATIONAL DE LA REC...

1. A a functional photoactive yellow protein (PYP) polypeptide comprising the sequence of SEQ ID NO: 48, or a sequence having at least 70% identity with the sequence of SEQ ID NO: 48, wherein said sequence further comprises one or more amino acid substitutions in the amino acid region at position 94-101 with reference to SEQ ID NO: 48, one of said substitutions being a proline at position 97 with reference to SEQ ID NO: 48, and wherein said polypeptide binds reversibly a fluorogenic chromophore with:a KD ranging from about 0.05 to about 10 ?M when measured at a temperature of about 25° C.; and/or
a koff ranging from about 1 to about 50 s?1 when measured at a temperature of about 25° C.; and/or
a kon ranging from about 0.1×107 to about 50×107 M?1s?1 when measured at a temperature of about 25° C.
US Pat. No. 10,138,279

COMPOSITIONS AND METHODS FOR BACILLUS ANTHRACIS VACCINATION

Regents of the University...

1. A method of inducing an immune response to Bacillus anthracis (B. anthracis) in a subject comprising intranasally administering an immunogenic composition comprising:A) a nanoemulsion, wherein the nanoemulsion comprises:
1. oil;
2. water;
3. ethanol;
4. a polysorbate surfactant selected from the group consisting of polyoxyethylene sorbitan monooleate and polyoxyethylene sorbitan monolaurate; and
5. cetylpyridinium chloride (CPC); and
B) recombinant protective antigen (rPA) of B. anthracis to the subject, wherein the administering generates a B. anthracis-specific immune response comprising generation of a serum anthrax lethal toxin (LeTx)-specific neutralizing antibody titer that is at least 10 fold greater than the serum LeTx-specific neutralizing antibody titer generated in a control subject administered an equal amount of rPA suspended in saline.
US Pat. No. 10,138,280

POLYPEPTIDES TARGETING GLYCOSYLATED MUC2 PROTEINS, METHODS OF SYNTHESIS, THEIR NUCLEIC ACIDS AND USES THEREOF

Institut Pasteur, Paris ...

1. An isolated nucleic acid molecule that comprises an open reading frame that encodes a polypeptide consisting of:a) SEQ ID NO: 3 having an additional cysteine residue at the N-terminus,
b) a fragment of SEQ ID NO: 3, wherein the fragment has an additional cysteine residue at the N-terminus, and wherein the fragment has a length of at least 20 contiguous amino acid residues,
c) a variant of SEQ ID NO: 3, wherein the variant has an additional cysteine residue at the N-terminus and has at least 85% identity with SEQ ID NO: 3, or
d) a variant of a fragment of SEQ ID NO: 3, wherein the variant of the fragment has an additional cysteine residue at the N-terminus, has a length of at least 20 contiguous amino acid residues, and has at least 85% identity with the fragment of SEQ ID NO: 3.
US Pat. No. 10,138,281

STABLE AMYLOID BETA MONOMERS AND OLIGOMERS

ALZINOVA AB, Gothenburg ...

1. A polypeptide, which is an amyloid precursor protein (APP), whereini) the amino acid alanine in position 692, as defined by the amino acid sequence of the human APP in SEQ ID NO: 12 is replaced with a cysteine; and
ii) the amino acid alanine in position 701, as defined by said amino acid sequence of said human APP in SEQ ID NO: 12 is replaced with a cysteine, wherein cleavage of said polypeptide derives a peptide fragment comprising the amino acid sequence L-V-F-F-C (SEQ ID NO: 13) corresponding to amino acids 17 to 21 of SEQ ID NO: 4 and the amino acid sequence C-I-I-G-L-M-V (SEQ ID NO: 14) corresponding to amino acids 30 to 36 of SEQ ID NO: 4, said peptide fragment comprising:
exactly two cysteines corresponding to Cys21 and Cys30 in SEQ ID NO: 4; and
exactly one disulfide bond, said exactly one disulfide bond is between said two cysteines corresponding to Cys21 and Cys30 in SEQ ID NO: 4, wherein said peptide fragment is resistant towards fibrillogenesis.
US Pat. No. 10,137,514

ABRASIVE ARTICLE AND METHOD OF FORMING

SAINT-GOBAIN ABRASIVES, I...

1. An abrasive article comprising:a substrate comprising an elongated body;
a plurality of discrete tacking regions overlying the substrate and defining gap regions between each of the discrete tacking regions of the plurality of discrete tacking regions;
abrasive particles overlying the plurality of discrete tacking regions;
a plurality of discrete formations overlying the substrate and spaced apart from the plurality of discrete tacking regions and the abrasive particles; and
a bonding layer overlying the plurality of discrete tacking regions, wherein at least a portion of the bonding layer is directly bonded to the substrate.
US Pat. No. 10,138,282

PEPTIDE ANTAGONIST OF LL-37

Indiana University Resear...

1. A composition comprising a peptide selected from the group consisting of SEQ ID NO: 1 (LL-29), SEQ ID NO: 2 (Peptide A), SEQ ID NO: 3 (LL8-37), SEQ ID NO: 22 (pig Proadrenomedullin Peptide (PAMP)-37), SEQ ID NO: 23 (sheep Myeloid Antimicrobial Peptide (SMAP)-29) and SEQ ID NO: 24 (rabbit Cationic Antimicrobial Peptide (CAP)-18), and an antibiotic, wherein the antibiotic is not attached to the peptide, and wherein the antibiotic is doxorubicin, kanamycin, or trimethoprim.
US Pat. No. 10,138,283

MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES

AMBRX, INC., La Jolla, C...

1. A bG-CSF polypeptide comprising the sequence of SEQ ID NO: 2, wherein position 134 of SEQ ID NO: 2 is substituted with a non-naturally encoded amino acid,wherein the non-naturally encoded amino acid is para-acetylphenylalanine,
wherein the non-naturally encoded amino acid is linked to a water soluble polymer comprising a poly(ethylene) glycol moiety,
wherein said water soluble polymer has a molecular weight of about 20 kDa, and
wherein said bG-CSF polypeptide is characterized by inducing a maximal absolute neutrophil count (ANC) about 10-fold greater than pre-treatment ANC, as measured about 72 hours after a single sub-cutaneous injection at 40 ?g/kg in a healthy bovine steer calf.
US Pat. No. 10,138,284

NON-STANDARD INSULIN ANALOGUES

Case Western Reserve Univ...

1. An insulin analogue comprising the insulin B-chain polypeptide containing a Cyclohexanylalanine substitution at a position corresponding to position B24 of wild type insulin and a glutamic acid substitution at a position corresponding to position B29 of wild type insulin; wherein optionally the insulin analogue comprises a lysine substitution at a position corresponding to position B3 of wild type insulin.
US Pat. No. 10,138,285

DIAGNOSIS OF A NEUROAUTOIMMUNE DISEASE COMPRISING MEASURING AUTOANTIBODIES TO FLOTILLIN1 AND/OR FLOTILLIN2

EUROIMMUN MEDIZINISCHE LA...

1. A method for detecting the presence of an autoantibody in a subject, comprising:obtaining a sample from a subject;
exposing a complex comprising 1) flotillin1 or a variant thereof and 2) flotillin2 or a variant thereof, which is immobilized on a solid carrier, to the sample from the subject; and
detecting whether the autoantibody is present in the sample by detecting the binding between the autoantibody and the complex.
US Pat. No. 10,138,286

METHODS AND COMPOSITIONS FOR INHIBITING THE EFFECTS OF AMYLOID BETA OLIGOMERS

The Board of Trustees of ...

1. A composition comprising a LILRB2 polypeptide consisting of the first two Ig-like domains of LILRB2, which are residues 24-223 of SEQ ID NO: 3; and an Fc domain.
US Pat. No. 10,138,287

UTERINE CANCER TREATMENTS

1. A method of treating cancer in a HLA-A*02+ patient having the cancer overexpressing a PGR polypeptide comprising the amino acid sequence of SEQ ID NO: 1 and presenting at its surface a peptide consisting of SEQ ID NO: 1 in complex with an MHC class I molecule, said method comprising administering to said patient an effective amount of activated antigen-specific CD8+ cytotoxic T cells to selectively eliminate the cancer cells, wherein said activated antigen-specific CD8+ cytotoxic T cells are produced by contacting CD8+ cytotoxic T cells with an antigen presenting cell presenting at its surface a peptide consisting of SEQ ID NO: 1 in the context of a complex with an MHC class I molecule in vitro, wherein the cancer is selected from the group consisting of uterine cancer, breast cancer, and hepatocellular cancer (HCC).
US Pat. No. 10,138,288

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS

1. A pharmaceutical composition comprising a peptide consisting of the amino acid sequence of ILQDGQFLV (SEQ ID NO. 157) in the form of a pharmaceutical acceptable salt and an adjuvant.
US Pat. No. 10,138,290

PROCESS FOR PROTEIN PRODUCTION

Novo Nordisk Healthcare A...

1. A large-scale, continuous perfusion process for producing a haemostasis protein, comprisingproviding a cell culture in suspension in a bioreactor, wherein the bioreactor is in fluid communication with a filter module, wherein the bioreactor volume is at least 500 L, and wherein the filter module mesh size is from about 0.1 ?m to about 2.9 ?m;
providing a dissolved oxygen concentration in the suspension of around 20% to 100%; and
flowing the cell culture suspension across the filter module in an alternating tangential flow, in order to separate haemostasis protein produced by the cell culture from the cells; and
culturing the cells to a target cell density below 80×106 cell s/ml.
US Pat. No. 10,138,292

CELL CULTURE MEDIUM

BIOLAMINA AB, Sundbyberg...

1. A system for maintaining human pluripotent stem cells, comprising:a chemically defined and xeno-free cell culture medium comprising from greater than zero to 3.9 ng/mL of basic fibroblast growth factor (bFGF), wherein the cell culture medium does not contain (1) insulin or an insulin substitute, and does not contain (2) transferrin or a transferrin substitute; and
a container having a substrate thereon, the substrate containing laminin-521 or laminin-511 for providing support to the human pluripotent stem cells.
US Pat. No. 10,138,293

BIVALENT, BISPECIFIC ANTIBODIES

HOFFMANN-LA ROCHE, INC., ...

1. A bivalent, bispecific antibody comprising two pairs of light chains and heavy chains, each light chain comprising a variable region and a constant region, each heavy chain comprising a variable region and a constant region, wherein:a) the light chain and heavy chain of the first of the two pairs specifically bind to a first antigen, wherein the light chain comprises the following domains in N-terminal to C-terminal direction VL, CL and the heavy chain comprises the following domains in N-terminal to C-terminal direction VH, CH1, CH2, CH3; and
b) the light chain and heavy chain of the second of the two pairs specifically bind to a second antigen, wherein the light chain comprises the following domains in N-terminal to C-terminal direction VH, CL and the heavy chain comprises the following domains in N-terminal to C-terminal direction VL, CH1, CH2, CH3.
US Pat. No. 10,138,038

ANTIMICROBIAL DETECTABLE CABLE TIE

1. A cable tie comprising:a body having a composition wherein the composition comprises a base plastic, an antimicrobial additive, and a detectable additive selected from a detectable metal additive, an X-ray detectable additive and combinations thereof, and wherein the antimicrobial additive includes silver ion complex and at least one selected from the group consisting of copper ion complex, polychloro phenoxy phenol derivative, quaternary ammonium compound, and zinc pyrithione derivative, and
a head having a barb comprising an antimicrobial metallic barb material,
wherein the body and the head are integrally connected, and wherein the antimicrobial metallic barb material comprises a copper alloy selected from the group consisting of C28000, C11000, C51000, C70600, C26000, and C75200.
US Pat. No. 10,138,294

TEMPERATURE SHIFT FOR HIGH YIELD EXPRESSION OF POLYPEPTIDES IN YEAST AND OTHER TRANSFORMED CELLS

ALDERBIO HOLDINGS LLC, L...

1. A method of producing a recombinant multi-subunit complex in yeast cells, comprising:(a) culturing at a first temperature yeast cells comprising one or more genes that encode said multi-subunit complex; and
(b) culturing said yeast cells at a second temperature and allowing said yeast cells to produce said multi-subunit complex;
wherein said first temperature is between 27.5° C. and 28.5° C., and said second temperature is between 30° C. and 31° C.,
wherein said method increases the yield of said protein and/or decreases the relative abundance of one or more product-associated variants relative to the same method effected without a difference between said first temperature and said second temperature, and
wherein the promoter or promoters which regulate the transcription of the one or more genes that encode said multi-subunit complex are not temperature inducible.
US Pat. No. 10,139,320

COMPOSITION FOR PROCESSING HISTOLOGICAL, POSTMORTEM, CYTOLOGICAL SAMPLES

Giacomo Madau, Cagliari ...

1. A method to process a biological sample, the method comprisingtreating the biological sample with a composition to process the biological sample, the composition comprising
at least one 2-ethylhexyl ester selected from the group consisting of 2-ethylhexyl benzoate, 2-ethylhexyl palmitate, 2-ethylhexyl cocoate, 2-ethylhexyl stearate, and 2-ethylhexyl acetate; and
ethyl alcohol and/or isopropyl alcohol,
wherein the at least one 2-ethylhexyl ester is in a concentration ranging from 30% to 70%, with respect to a total volume of the composition, the ethyl alcohol is in a concentration ranging from 20% to 60% with respect to the total volume of the composition and the isopropyl alcohol is in a concentration ranging from 10% to 30% with respect to the total volume of the composition.
US Pat. No. 10,139,321

MUCOLYTIC TABLET FOR A SAMPLE COLLECTION DEVICE

Alpha-Tec Systems, Inc., ...

1. A mucolytic tablet for a sample collection device, comprising:(i) 15% to 65% by weight of N-acetyl L-cysteine (NALC);
(ii) 6% to 30% by weight of a buffering agent;
(iii) 10% to 14% by weight of a water soluble anti-adherent; and
(iv) 2% to 10% by weight of at least one water soluble chelating and lubricating agent,
wherein the mucolytic tablet solubilizes in a resuspension buffer.
US Pat. No. 10,138,297

ANTIBODY NEUTRALIZERS OF HUMAN GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR

AMGEN RESEARCH (MUNICH) G...

1. A method of treating an inflammatory disease, comprising administering an effective dose of a human monoclonal antibody or fragment thereof which specifically binds to and neutralizes primate GM-CSF, wherein the antibody or fragment thereof comprises in its light chain variable region a CDR1 comprising an amino acid sequence as set out in SEQ ID NO: 16, a CDR2 comprising an amino acid sequence as set out in SEQ ID NO: 17 and a CDR3 comprising an amino acid sequence as set out in SEQ ID NO: 18; and comprising in its heavy chain variable region a CDR1 comprising an amino acid sequence as set out in SEQ ID NO: 14, a CDR2 comprising an amino acid sequence as set out in SEQ ID NO: 15 and a CDR3 comprising an amino acid sequence as set out in any of SEQ ID NOS: 1-13 or 56, wherein the inflammatory disease is rheumatoid arthritis (RA), asthma, or multiple sclerosis (MS).
US Pat. No. 10,138,298

ANTI-IL-2 ANTIBODIES AND COMPOSITIONS AND USES THEREOF

The Regents of the Univer...

1. An isolated antibody or antigen-binding portion thereof that specifically binds human IL-2, said antibody comprising: a heavy chain complementarity determining region 1 (HCDR1) comprising SEQ ID NO:127, a heavy chain complementarity determining region 2 (HCDR2) comprising SEQ ID NO:130, a heavy chain complementarity determining region 3 (HCDR3) comprising SEQ ID NO:132, a light chain complementarity determining region 1 (LCDR1) comprising SEQ ID NO:133, a light chain complementarity determining region 2 (LCDR2) comprising SEQ ID NO:134, and a light chain complementarity determining region 3 (LCDR3) comprising SEQ ID NO:135.
US Pat. No. 10,138,299

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

Bristol-Myers Squibb Comp...

1. A method of treating a tumor in a human subject in need thereof, comprising administering to the subject about 10 mg/kg of an anti-PD-L1 antibody every 2 weeks, wherein the anti-PD-L1 antibody is administered intravenously over 60 minutes infusion;wherein the tumor is derived from a bladder cancer of; and wherein the tumor is refractory to a platinum based chemotherapy.
US Pat. No. 10,138,300

ANTI-VEGFR ANTIBODY AND USES THEREOF

DEVELOPMENT CENTER FOR BI...

1. An antibody or antigen-binding fragment thereof that specifically binds to an epitope in human vascular endothelial growth factor receptor 2 (VEGFR-2) or a fragment thereof; wherein the human vascular endothelial growth factor receptor 2 has the amino acid sequence of SEQ ID NO: 1, and the epitope comprises:the serine residue at position 711, the lysine residue at position 716, the aspartic acid residue at position 717, and the arginine residues at positions 725 and 726 of SEQ ID NO: 1; which antibody or antigen-binding fragment thereof comprises complementarity determining regions (CDRs) of a heavy chain variable region and complementarity determining regions of a light chain variable region, wherein the complementarity determining regions of the heavy chain variable region comprises CDRH1, CDRH2 and CDRH3 regions, and the complementarity determining regions of the light chain variable region comprises CDRL1, CDRL2 and CDRL3 regions, and the CDRH1 region comprises the amino acid sequence of SEQ ID NO: 4; the CDRH2 region comprises the amino acid sequence of SEQ ID NO: 5; the CDRH3 region comprises the amino acid sequence of SEQ ID NO: 6; the CDRL1 region comprises the amino acid sequence of SEQ ID NO: 7; the CDRL2 region comprises the amino acid sequence of SEQ ID NO: 8; and the CDRL3 region comprises the amino acid sequence of SEQ ID NO: 9.
US Pat. No. 10,138,301

MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2

GALAXY BIOTECH, LLC, Cup...

1. An isolated monoclonal antibody (mAb) that binds human fibroblast growth factor receptor 2 isoform IIIb (FGFR2 IIIb) comprising a light chain variable region comprising CDR1, CDR2, and CDR3 respectively defined by residues 24-34, 50-56, and 89-97 of SEQ ID NO. 1 and comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 respectively defined by residues 31-35, 50-66 and 99-103 of SEQ ID NO:4.
US Pat. No. 10,138,558

PRETREATMENT AGENT FOR ELECTROLESS PLATING, AND PRETREATMENT AND PRODUCTION OF PRINTED WIRING BOARD USING SAME

1. A pretreatment agent for electroless plating, comprising:a silane coupling agent;
a surfactant; and
ethylene-based glycol butyl ethers of formula: C4H9—(OC2H4)nOH where n is an integer of 1 to 4, and/or propylene-based glycol butyl ethers of formula: C4H9—(OC3H6)nOH where n is an integer of 1 to 4.
US Pat. No. 10,137,534

BONDING WIRE FOR SEMICONDUCTOR DEVICE

Nippon Micrometal Corpora...

1. A bonding wire for a semiconductor device, the bonding wire comprising:a Cu alloy core material; and
a Pd coating layer formed on a surface of the Cu alloy core material, wherein
the bonding wire contains at least one element selected from Ni, Zn, Rh, Ir, and Pt,
a concentration of the elements in total relative to the entire wire is 0.03% by mass or more and 2% by mass or less, or
the bonding wire contains In, a concentration of In is 0.07% by mass or more and 2% by mass or less relative to the entire wire,
when measuring crystal orientations on a cross-section of the core material in a direction perpendicular to a wire axis of the bonding wire, a crystal orientation <100> angled at 15 degrees or less to the wire axis direction has a proportion of 50% or more among crystal orientations in the wire axis direction, and
an average crystal grain size in the cross-section of the core material in the direction perpendicular to the wire axis of the bonding wire is 0.9 ?m or more and 1.3 ?m or less.
US Pat. No. 10,138,302

METHODS FOR TREATING RHEUMATOID ARTHRITIS BY ADMINISTERING INTERLEUKIN-6 RECEPTOR ANTIBODIES

Ablynx N.V., Ghent-Zwijn...

1. A method for treating rheumatoid arthritis in a human subject comprising administering to the human subject a polypeptide that specifically binds interleukin-6receptor (IL-6R), wherein the amount of the polypeptide administered is effective:to increase total soluble interleukin-6 receptor (sIL-6R) levels in serum to at least 400 ng/ml and to maintain total sIL-6R levels in serum of at least 400 ng/ml;
to increase total IL-6 levels in serum to at least 40 pg/ml and to maintain total IL-6 levels in serum of least 40 pg/ml;
to reduce C-reactive protein (CRP) levels in serum below 10 mg/l and to maintain CRP levels in serum below 10 mg/l;
to reduce CRP levels in serum by 50% or more compared to baseline levels and to maintain CRP levels in serum at 50% or more reduction compared to baseline levels;
to reduce Erythrocytes Sedimentation Rate (ESR) levels in serum by 30% or more compared to baseline levels and to maintain ESR levels in serum at 30% or more reduction compared to baseline levels;
to reduce fibrinogen levels in serum by 30% or more compared to baseline levels and to maintain fibrinogen levels in serum at 30% or more reduction compared to baseline levels; and/or
to reduce serum amyloid A levels by 30% or more compared to baseline levels and to maintain serum amyloid A levels at 30% or more reduction compared to baseline levels; for at least 4 weeks after administration; and
wherein the polypeptide comprises SEQ ID NO: 34;
and wherein the polypeptide is administered in an amount from 3 mg/kg to 6 mg/kg every 4 to 8 weeks.
US Pat. No. 10,138,559

CHEMICAL CONVERSION AGENT AND METAL SURFACE TREATMENT METHOD

NIPPON PAINT SURF CHEMICA...

1. A chemical conversion agent comprising one, or two or more metal element(s) (A) selected from the group consisting of zirconium, titanium, and hafnium,a vanadium element (B), and
a resin (C),
wherein the chemical coversion agent only includes, as the resin (C), a polyvinyl alcohol-based resin (C1) consisting of at least one of polyvinyl alcohol and a derivative thereof, and one, or two or more metal ion-crosslinkable polymer(s) (C2),
wherein a polymerization degree of the polyvinyl alcohol-based resin (C1) is 500 to 1,100,
wherein the metal ion-crosslinkable polymer (C2) is one, or two or more polymer(s) selected from the group consisting of polyacrylic acid, phosphoric acid polymer, phosphonic acid polymer, water-soluble or water-dispersible epoxy polymer, water-soluble or water-dispersible urethane-based polymer, and polyester,
wherein the value of a ratio (Wa/Wb) of the mass-based total content (Wa) of the metal element (A) to the mass-based content (Wb) of the vanadium element (B) is 0.1-15,
wherein the value of a ratio ((Wa+Wb)/Wc1) of the mass-based total content (Wa+Wb) of the metal element (A) and the vanadium element (B) to the mass-based total content (Wc1) of the polyvinyl alcohol-based resin (C1) is 0.25-15, and
wherein the value of a ratio (Wc2/(Wc1+Wc2)) of the mass-based total content (Wc2) of the metal ion-crosslinkable polymer (C2) to the mass-based total content (Wc1+Wc2) of the polyvinyl alcohol-based resin (C1) and the metal ion-crosslinkable polymer (C2) is 0.4 or less.
US Pat. No. 10,138,303

HETERODIMERIC PROTEINS AND METHODS FOR PRODUCING AND PURIFYING THEM

RINAT NEUROSCIENCE CORP.,...

1. A heterodimeric protein comprising:a hinge region comprising a first immunoglobulin-like hinge polypeptide and a second immunoglobulin-like hinge polypeptide which interact together to form a dimeric hinge interface, wherein electrostatic interactions between one or more charged amino acids within the hinge interface favor interaction between the first and second hinge polypeptides over interaction between two first hinge polypeptides or two second hinge polypeptides, thereby promoting heterodimer formation over homodimer formation, wherein the hinge region is a human IgG1 hinge region, wherein the first hinge polypeptide comprises at least one amino acid modification relative to a wild-type IgG hinge region; wherein the wild-type amino acid in the first hinge polypeptide is replaced with an amino acid having an opposite charge to the corresponding amino acid in the second hinge polypeptide, wherein the amino acid modification in the hinge region comprises Asp221 as shown at FIG. 6A, and further comprising an immunoglobulin-like CH3 region comprising a first CH3 polypeptide fused to the first hinge polypeptide and a second CH3 polypeptide fused to the second hinge polypeptide, wherein the first CH3 polypeptide and the second CH3 polypeptide comprise at least one amino acid modification relative to a wild-type IgG1 CH3 region sequence at a position selected from the group consisting of Tyr349, Leu368, Phe405, and Lys409 (EU numbering scheme) as shown at FIG. 10.
US Pat. No. 10,138,560

METHODS AND SYSTEMS UTILIZING A BORON-CONTAINING CORROSION INHIBITOR FOR PROTECTION OF TITANIUM SURFACES

Halliburton Energy Servic...

1. A method comprising:contacting a metal surface consisting of titanium or a titanium alloy with a corrosion inhibitor composition comprising a boron-containing compound, wherein the boron-containing compound comprises a boron-alkanolamine complex;
interacting the metal surface with a fluid phase comprising hydrofluoric acid or acidic fluoride ions; and
suppressing corrosion of the metal surface by the hydrofluoric acid or acidic fluoride ions with the boron-containing compound.
US Pat. No. 10,137,280

SYSTEM AND METHOD FOR TREATMENT OF HEMORRHAGIC STROKE

InCube Labs, LLC, San Jo...

1. A method for treating a cerebral aneurysm, the method comprising:advancing a microcatheter having a delivery lumen to the site of the aneurysm;
delivering a carrier containing a first agent and a second agent to the aneurysm through the delivery lumen of the microcatheter so as to at least partially fill a sac of the aneurysm; wherein the first agent comprises an anti-inflammatory agent and the second agent comprises a member of the transforming growth factor-? family; and
controllably releasing the first and second agents from the carrier to the site of the aneurysm,
wherein the carrier comprises a first gel component including the first agent and a second gel component including the second agent,
wherein the first gel component has a first viscosity selected to release the first agent at a first rate of release, and
wherein the second gel component has a second viscosity different from the first viscosity, the second viscosity being selected to release the second agent at a second rate of release slower than the first rate of release.
US Pat. No. 10,138,304

METHODS FOR INCREASING THE EXTRACTABLE RUBBER CONTENT OF NON-HEVEA PLANT MATTER

Bridgestone Corporation, ...

1. A method for increasing the extractable rubber content of non-Hevea plant matter without unduly increasing the extractable resin content comprising:utilizing a quantity of chopped non-Hevea plant matter having an average length of ½? to 4? and a maximum moisture content of 15 weight % and subjecting the chopped non-Hevea plant matter to at least one of
hammer milling utilizing a screen size of less than ½? and greater than or equal to 3/16?; and
roller milling with corrugated rolls having no more than 8 corrugations per inch,
thereby producing a quantity of milled non-Hevea plant matter having a maximum moisture content of 15 weight %, an extractable rubber content at least 30% higher than the pre-milled chopped non-Hevea plant matter and an extractable resin content of no more than 3 times the extractable rubber content.
US Pat. No. 10,138,306

METHACRYLIC ACID PRODUCTION METHOD

University of Georgia Res...

1. A method of producing methacrylic acid comprising reacting a substrate with a palladium nitrate catalyst comprising a hydrotalcite under conditions sufficient to produce methacrylic acid in a single step, wherein the substrate is selected from the group consisting of 2-hydroxyisobutyric acid or salts thereof, itaconic acid or salts thereof, citric acid or salts thereof, citramalic acid or salts thereof, and combinations thereof.
US Pat. No. 10,138,308

CATALYST COMPONENT FOR THE PREPARATION OF NUCLEATED POLYOLEFINS

BOREALIS AG, (AT)

1. A process of obtaining a catalyst composition containing a catalyst component, the process comprising:a1) providing a solution of at least a Group 2 metal alkoxy compound (Ax) being the reaction product of a Group 2 metal compound (MC) and a monohydric alcohol (A) comprising in addition to the hydroxyl moiety at least one ether moiety optionally in an organic liquid reaction medium; or
a2) providing a solution of at least a Group 2 metal alkoxy compound (Ax?) being the reaction product of a Group 2 metal compound (MC) and an alcohol mixture of the monohydric alcohol (A) and a monohydric alcohol (B) of formula ROH, optionally in an organic liquid reaction medium; or
a3) providing a solution of a mixture of the Group 2 metal alkoxy compound (Ax) and a Group 2 metal alkoxy compound (Bx) being the reaction product of a Group 2 metal compound (MC) and the monohydric alcohol (B), optionally in an organic liquid reaction medium; or
a4) providing a solution of Group 2 metal alkoxy compound of formula M(OR1)n(OR2)mX2-n-m or mixture of Group 2 alkoxides M(OR1)n?X2-n? and M(OR2)m?X2-m?, where M is Group 2 metal, X is halogen, R1 and R2 are different alkyl groups of C2 to C16 carbon atoms, and 0 b) adding said solution from step a) to at least one compound (TC) of a transition metal of Group 4 to 6, and
c) obtaining the solid catalyst component particles,
d) washing said solidified particles,
e) recovering the solidified particles of the olefin polymerisation catalyst component, wherein an electron donor is added at any step prior to step c) and is a non-phthalic internal electron donor, and
wherein the catalyst component is further modified by a polymeric nucleating agent comprising vinyl compound units;
wherein the catalyst component is washed in step d) at least three times with at least one toluene and at least one TiCl4 washing step and 1 to 3 further washing steps with an aromatic and/or aliphatic hydrocarbon selected from toluene, heptane or pentane; and
wherein internal donor is added to either the toluene wash step and/or to the TiCl4 wash step, whereby the amount of donor added to the washing steps is in the range of 10 to 60 wt % of the total amount of donor used in catalyst preparation steps a) to d).
US Pat. No. 10,138,566

SEALING ANODIZED ALUMINUM USING A LOW-TEMPERATURE NICKEL-FREE PROCESS

MacDermid Acumen, Inc., ...

1. A method for sealing an anodized aluminum or anodized aluminum alloy surface comprising:(i) contacting the anodized surface with a sealing composition comprising a source of lithium ions, a source of fluoride ions, and a complexing agent, followed by;
(ii) contacting the anodized surface with a passivation composition wherein the passivation composition comprises a source of metal ions and a complexing agent;
wherein the surface of the anodized aluminum or anodized aluminum alloy becomes corrosion resistant, and
wherein the temperature of the passivation composition is less than 80° C.
US Pat. No. 10,138,310

PREPARATION OF LLDPE RESINS AND FILMS HAVING LOW GELS

Equistar Chemicals, LP, ...

1. A process for making a linear low density polyethylene resin comprising the steps of:copolymerizing ethylene with a comonomer selected from 1-butene and 1-hexene, and wherein the comonomer used in an amount within the range of 5-10% by weight of ethylene to produce a linear low density polyethylene;
wherein the copolymerizing step is performed in the presence of hydrogen, an inert gas selected from nitrogen and carbon dioxide, and
a Ziegler-Natta catalyst comprising:
a MgCl2 support,
a Ti(IV) complex, and
an internal electron donor comprising a cyclic ether; and
wherein Ziegler-Natta catalyst is formed by first contacting the MgCl2 support with the Ti(IV) complex to form an intermediate product, and the intermediate product is then contacted with the internal electron donor to produce the Ziegler-Natta catalyst;
wherein the Ziegler-Natta catalyst has an Mg/Ti molar ratio greater than or equal to 7, and an internal electron donor/Ti molar ratio between 5 and 20; and
wherein the linear low density polyethylene resin has a gel defect area less than or equal to 25 ppm;
wherein the catalyst is characterized by an X-ray diffraction spectrum which, in the range of 2? diffraction angles between 5.0° and 20.0°, has at least three main diffraction peaks: 2? of 7.2±0.2°, 11.5±0.2°, and 14.5±0.2°; and
wherein the peak at 2? of 7.2±0.2° is most intense and the peak at 11.5±0.2° has an intensity less than 90% of the intensity of the peak at 2? of 7.2±0.2°.
US Pat. No. 10,138,569

WELD CLEANING FLUID

Ensitech IP PTY LLP, Emu...

1. A stainless steel cleaning composition, comprising:an aqueous solution having a pH that is approximately neutral, said aqueous solution having from more than 30% to 60% by weight of a phosphoric acid salt, and having up to 20% by weight of a salt of a polyaminocarboxylic acid as a sequestering or chelating agent,
wherein said acid salt is selected to induce passivation of stainless steel through oxidation of chromium atoms within the stainless steel, and
all optional components of said composition are selected to be chemically unreactive with, and non-chemically-bonding to, metals.
US Pat. No. 10,138,314

RUBBER GRAFT COPOLYMER, AND THERMOPLASTIC RESIN COMPOSITION CONTAINING RUBBER GRAFT COPOLYMER

KANEKA CORPORATION, Osak...

1. A rubber graft copolymer comprising a core layer containing a rubber polymer and a shell layer grafted on the core layer satisfying all of the following (1) to (7):(1) the rubber graft copolymer polymerized under the presence of an alkaline metal salt of a phosphate compound,
(2) the rubber graft copolymer obtained by contacting a solution containing an alkaline earth metal chloride to a latex containing the rubber graft copolymer obtained by the emulsion polymerization to coagulate the copolymer,
(3) the rubber graft copolymer in which the phosphate compound remains as an alkaline earth metal salt in the rubber graft copolymer, the remaining amount of the alkaline earth metal salt of the phosphate compound is 400 ppm or more and 3000 ppm or less as an alkaline earth metal on a mass basis,
(4) the rubber graft copolymer obtained by polymerizing at conditions of pH of 5.0 to 9.0,
(5) the rubber graft copolymer in which the rubber polymer is a polybutadiene or a poly (butadiene-styrene),
(6) a concentration of monomers used in the polymerization of the shell layer is (i) 60 to 80% by mass of methyl methacrylate and 20 to 40% by mass of styrene, or (ii) 70 to 99% by mass of methyl methacrylate and 1 to 30% by mass of butylacrylate, or (iii) 30 to 40% by mass of glycidyl methacrylate, 45 to 55% by mass of methylmethacrylate, and 5 to 25% by mass of styrene, per 100% by mass of monomers constituting the shell layer, and
(7) the alkaline metal salt of the phosphate compound is polyoxyalkylene alkyl phenyl ether phosphate salt or polyoxyalkylene alkyl ether phosphate salt.
US Pat. No. 10,138,316

AMPHIPHILIC BRANCHED POLYDIORGANOSILOXANE MACROMERS

Novartis AG, Basel (CH)

1. An amphiphilic branched polydiorganosiloxane macromer, comprising:(1) at least first one polydiorganosiloxane polymer chain having two terminal methacryloyl groups; and
(2) at least one first hydrophilic chain;
(3) at least one second hydrophilic polymer chain; and
(4) at least one second polydiorganosiloxane polymer chain at least one end of which is covalently connected to the second hydrophilic polymer chain,
wherein the first and second polydiorganosiloxane chains are derived from an ?,?-dimethacryloyl-terminated polydiorganosiloxane vinylic crosslinker comprising one or more ATRP-containing siloxane units having one substituent having an ATRP initiator,
wherein the first hydrophilic chain is anchored covalently onto one single ATRP-containing siloxane unit of the first or second polydiorganosiloxane chain at one of the two ends of the first hydrophilic polymer chain and has one first terminal group at the other one of the two ends of the first hydrophilic polymer chain,
wherein the second hydrophilic polymer chain is (a) anchored covalently onto one single ATRP-containing siloxane unit of the first polydiorganosiloxane chain at one of the two ends of the second hydrophilic polymer chain, (b) has one second terminal group at the other one of the two ends of the second hydrophilic polymer chain, and (c) is covalently connected to covalently connected to one of the two ends of the second polydiorganosiloxane chain,
wherein the first and second terminal groups independent of each other are (meth)acryloxy group, (meth)acryloxy-C2-C4 alkoxy group, (meth)acrylamido-C2-C4 alkoxy group, (meth)acryloxy-C2-C4 alkylamino group, (meth)acrylamido-C2-C4 alkylamino group, C1-C6 substituted or unsubstituted alkoxy group, C2-C6 substituted or unsubstituted alkanoyloxy group, or C1-C6 substituted or unsubstituted alkylamino group, wherein the first and second hydrophilic polymer chains are composed of monomeric units of at least one hydrophilic vinylic monomer selected from the group consisting of (meth)acrylamide, N,N-dimethyl (meth)acrylamide, dimethylaminoethyl (meth)acrylate, dimethylaminoethyl (meth)acrylamide, N-vinyl-2-pyrrolidone, N-vinyl-N-methyl isopropylamide, N-vinyl-N-methyl acetamide, N-vinyl formamide, N-vinyl acetamide, N-vinyl isopropylamide, N-vinyl-N-methyl acetamide, hydroxyethyl (meth)acrylate, hydroxyethyl (meth)acrylamide, hydroxypropyl (meth)acrylamide, glycerol methacrylate (GMA), polyethylene glycol (meth)acrylate, polyethylene glycol C1-C4-alkyl ether (meth)acrylate having a number average molecular weight of up to 1500, and mixtures thereof.
US Pat. No. 10,138,576

BIOCOMPATIBLE HYDROPHILIC COMPOSITIONS

3M INNOVATIVE PROPERTIES ...

1. A nonwoven web of fibers, wherein the fibers comprise a blend comprising:at least one thermoplastic aliphatic polyester;
an alkyl, alkenyl, aralkyl, or alkaryl anionic surfactant incorporated in the polyester; wherein the surfactant is selected from the group consisting of alkyl sulfate, alkenyl sulfate, alkaryl sulfate, aralkyl sulfate, alkylalkoxylated sulfate, alkyl sulfonate, alkenyl sulfonate, alkaryl sulfonate, aralkyl sulfonate, alkylalkoxylated sulfonate, alkyl phosphonate, alkenyl phosphonate, alkaryl phosphonate, aralkyl phosphonate, alkyl phosphate, alkenyl phosphate, alkaryl phosphate, aralkyl phosphate, alkyl alkoxylated phosphate, di(C8-C18) sulfosuccinate salts, C8-C22 alkyl sarcosinate salts, C8-C22 alkyl lactylate salts, and combinations thereof; wherein the surfactant is present in a concentration sufficient to make the nonwoven web durably hydrophilic and absorbent and instantaneously wettable; and
a surfactant carrier;
wherein the fibers are 20 micrometers or less in diameter;
wherein the surfactant is soluble in the carrier at greater than 10% by weight such that the surfactant and carrier form a visually transparent solution in a 1-cm path length glass vial when heated to 150° C.
US Pat. No. 10,138,320

COMB-BLOCK HIGH DENSITY POLYETHYLENES AND METHODS OF MAKING THEM

ExxonMobil Chemical Paten...

1. A process for making a polyethylene composition comprising:contacting, at a temperature of at least 100° C., ethylene with a first salan catalyst precursor and an activator to form branched vinyl/vinylidene-terminated high density polyethylene (“bVT-HDPE”) having a number average molecular weight (Mn) of at least 5,000 g/mole;
contacting, at a temperature of at least 100° C., the bVT-HDPE with ethylene and a second metallocene catalyst precursor and an activator to form a comb-block HDPE; and
isolating a polyethylene composition.
US Pat. No. 10,138,577

POLYPHENYLENE SULFIDE FIBERS, AND MANUFACTURING METHOD THEREFOR

Toray Industries, Inc., ...

1. A poly(phenylene sulfide) fiber containing 1-10% by weight of a poly(phenylene sulfide) oligomer having a weight-average molecular weight of 5,000 or less, having a difference between a cold crystallization heat quantity (?Hc) and a crystal melting heat quantity (?Hm) during temperature rising in DSC, ?Hm??Hc, of 25 J/g or larger, and having an elongation of less than 40% and a strength of 3.0 cN/dtex or higher.
US Pat. No. 10,139,345

MAGNETIC AND RAMAN BASED METHOD FOR PROCESS CONTROL DURING FABRICATION OF CARBON NANOTUBE BASED STRUCTURES

THE UNITED STATES OF AMER...

13. A method for process control during fabrication of carbon nanotube structures, the method comprising:providing a carbon nanotube starting material;
forming the composite structure with the carbon nanotube starting material under one or more fabrication process parameters; and
monitoring a magnetic property of the composite structure while forming the composite structure.
US Pat. No. 10,138,321

PROCESS FOR PRODUCTION OF OXYMETHYLENE COPOLYMER

MITSUBISHI GAS CHEMICAL C...

1. A method for producing an oxymethylene copolymer, comprising a polymerization step for cationically polymerizing trioxane and a comonomer at a polymerization temperature of from 135 to 300° C. in the presence of at least one salt of a protonic acid having a molecular weight of 1,000 or less, and at least one polymerization initiator selected from the group consisting of protonic acids having a molecular weight of 1,000 or less, protonic acid anhydrides having a molecular weight of 1,000 or less, and protonic acid ester compounds having a molecular weight of 1,000 or less, wherein the trioxane and comonomer used in the polymerization step contain metal components in a total concentration of 300 ppb by mass or less.
US Pat. No. 10,138,326

METHOD OF PRODUCING COPOLYESTER MATERIAL WITH PEPTIDE AND COPOLYESTER MATERIAL WITH PEPTIDE THEREOF

Camangi Corporation, Tai...

1. A method of producing copolyester material with peptide, comprising:putting ethylene glycol (EG), collagen peptide, and benzenedicarboxylic acid into a container, and mixing the ethylene glycol, the collagen peptide, and the benzenedicarboxylic acid to form a mixture, wherein in the mixture, a molar ratio of the collagen peptide, the ethylene glycol, and the benzenedicarboxylic acid is (0.47-0.60): (0.90-1.10): (1.14-1.26); heating the mixture for executing an esterification reaction, to produce esters and water;
heating the esters to a first temperature, and stirring the esters via a mixer;
in a specific period, decreasing a pressure in the container to a first pressure for executing a polycondensation reaction; and
decreasing the pressure in the container to a second pressure, and stirring the esters via the mixer, to produce a copolyester material with peptide.
US Pat. No. 10,138,328

METHOD FOR PRODUCING POLYETHER CARBONATE POLYOLS

Covestro Deutschland AG, ...

1. A process for preparing polyether carbonate polyols, comprising reacting alkylene oxide with carbon dioxide in the presence of an H-functional starter compound and double metal cyanide catalyst, wherein the process comprises:(?) optionally, pretreating a double metal cyanide catalyst (DMC catalyst) at a temperature of 50 to 200° C. and/or reduced pressure (absolute) of 10 mbar to 800 mbar in a first reactor,
(?) contacting the double metal cyanide catalyst and suspension medium with alkylene oxide to obtain a first reaction mixture in a first reactor;
and
(?) continuously adding the first reaction mixture, alkylene oxide, carbon dioxide and optionally H-functional starter compound to a second reactor,
wherein at least one H-functional starter compound is added at least in one of steps (?) and (?) and
wherein reaction products formed in step (?) are withdrawn continuously from the second reactor.
US Pat. No. 10,138,330

SILICONE ELASTOMERS CAPABLE OF LARGE ISOTROPIC DIMENSIONAL CHANGE

Lawrence Livermore Nation...

1. A method for making a microfluidic device, comprising forming a microfluidic pattern comprising at least one line having a width of 500 ?m or less with a silicone-based elastomer, wherein the silicone-based elastomer comprises a network of crosslinked polysiloxane having its internal space occupied by a guest molecule, and removing the guest molecule from the silicone-based elastomer to isotropically reduced the volume of the silicone-based elastomer by at least 20%.
US Pat. No. 10,138,332

METHODS FOR TREATING LIGNOCELLULOSIC MATERIALS

VIRDIA, INC., Raceland, ...

1. A product comprising or derived from a lignin composition having a degree of condensation of less than 0.9 and characterized by at least two characteristics selected from the group consisting of:(i) lignin aliphatic hydroxyl group in an amount up to 2 mmole/g;
(ii) at least 2.5 mmole/g lignin phenolic hydroxyl group;
(iii) less than 0.40 mmole/g lignin carboxylic hydroxyl group;
(iv) sulfur in an amount up to 1% weight/weight;
(v) nitrogen in an amount up to 0.5% weight/weight;
(vi) 5% degradation temperature higher than 220° C.;
(vii) 10% degradation temperature higher than 260° C.;
(viii) less than 1% ash weight/weight;
(ix) a formula of CaHbOc; wherein a is 9, b is less than 12 and c is less than 3.5;
(x) a methoxyl content of at least 0.8;
(xi) an O/C weight ratio of less than 0.4; and
(xii) a glass transition elevation between a first and a second heat cycle as measured by differential scanning calorimetry according to DIN 53765 in the range of 10 to 30° C.;wherein the product is selected from the group consisting of: carbon fibers, protective coatings, lignosulfonates, dispersants, emulsifiers, complexants, flocculants, agglomerants, pelletizing additives, resins, adhesives, binders, absorbents, toxin binders, films, rubbers, elastomers, sequestrants, solid fuels, paints, dyes, plastics, wet spun fibers, melt spun fibers, flame retardants, a non-woven fabric, a woven fabric, insulation material, sports equipment, automotive parts, airplane or helicopter parts, boat hulls or portions thereof, and loudspeakers.
US Pat. No. 10,138,334

DRY WATER SOLUBLE POLYMER PARTICLES

Water Mark Technologies, ...

1. A method of reducing friction during fracturing a subterranean formation, comprising:introducing micronized dry water soluble polymer (DWSP) particles having a mean particle size ranging from about 115 to about 300 microns as a friction reducer directly into a reservoir containing a fracture fluid prior to pumping the fracture fluid from the reservoir into a well bore formed in a subterranean formation, wherein the DWSP particles are dispersed in a fluid that does not dissolve the DWSP particles prior to the introduction into the reservoir, wherein the fluid that does not dissolve the DWSP particles is an oil; and
upon the introduction of the friction reducer, pumping the fracture fluid from the reservoir into the well bore formed in the subterranean formation to fracture the subterranean formation,
wherein a desired reduction in the pressure at the head of the well bore in the subterranean formation is achieved in less than about 30 seconds of pumping the fracture fluid,
wherein the micronized DWSP particles comprise:
a DWSP,
wherein the DWSP is selected from the group consisting of a dry anionic water soluble polymer, a dry cationic water soluble polymer, a dry nonionic water soluble polymer, and mixtures thereof.
US Pat. No. 10,138,593

SIZING AGENT-COATED CARBON FIBERS, PROCESS FOR PRODUCING SIZING AGENT-COATED CARBON FIBERS, PREPREG, AND CARBON FIBER REINFORCED COMPOSITE MATERIAL

Toray Industries, Inc., ...

1. Sizing agent-coated carbon fibers comprising:a sizing agent coating that includes:
an aliphatic epoxy compound (A) that has three or more epoxy groups and at least one hydroxy group in a molecule,
an aromatic epoxy compound (B1) as a type of aromatic compound (B), and
an aromatic ester compound (C1); and
carbon fibers coated with the sizing agent,whereinthe sizing agent contains the aliphatic epoxy compound (A) in an amount of 35 to 65% by mass relative to the total amount of the sizing agent exclusive of solvent;
the sizing agent contains the aliphatic epoxy compound (A) and the aromatic epoxy compound (B1) in a mass ratio (A)/(B1) of 52/48 to 80/20;
the sizing agent contains the aromatic ester compound (C1) in an amount of 2 to 35% by mass relative to the total amount of the sizing agent exclusive of solvent;
each of the aliphatic epoxy compound (A) and the aromatic epoxy compound (B1) has a surface tension of 35 to 45 mJ/m2 at 125° C.;
the sizing agent-coated carbon fibers have an (a)/(b) ratio of 0.50 to 0.90, wherein (a) is a height (cps) of a component at a binding energy (284.6 eV) assigned to CHx, C—C, and C?C and (b) is a height (cps) of a component at a binding energy (286.1 eV) assigned to C—C in a C1s core spectrum of a surface of the sizing agent applied onto the carbon fibers analyzed by X-ray photoelectron spectroscopy using AlK?1,2 as an X-ray source at a photoelectron takeoff angle of 15°; and
the carbon fibers have a surface carboxy group concentration COOH/C of 0.003 to 0.015 and a surface hydroxy group concentration COH/C of 0.001 to 0.050 determined by chemical modification X-ray photoelectron spectroscopy.
US Pat. No. 10,139,361

PROTEOLYSIS DETECTION

The University of Queensl...

1. A method for detecting or monitoring proteolysis of a synthetic proteinaceous matrix comprising:contacting at least a portion of the synthetic proteinaceous matrix with a biological sample, wherein the synthetic proteinaceous matrix is impregnated with an electroactive species, the synthetic proteinaceous matrix is contained in or placed on a support, the synthetic proteinaceous matrix is in contact with at least a portion of a working electrode or a counter electrode, and the biological sample comprises a biological fluid;
applying a potential to the working electrode, thereby generating an electrochemical current through the working electrode;
measuring the electrochemical current at a plurality of times to obtain a plurality of current measurements; and
comparing at least two of the plurality of current measurements wherein a difference between the at least two current measurements is indicative of degradation of the synthetic proteinaceous matrix in the presence of the biological sample.
US Pat. No. 10,138,337

POLYMER/POTASSIUM PERMANGANATE COMPOSITE FILM AND PREPARATION METHOD THEREOF

FUZHOU UNIVERSITY, Fuzho...

1. A process for preparing a polymer/potassium permanganate composite film, comprising the following steps:Step (1): mixing polymethylhydrosiloxane or KH-570 and zinc stearate with potassium permanganate well at a mass ratio of 1-3:1-3:100, then heating the mixture under the temperature of 130-150° C. for 20-40 minutes to obtain a modified potassium permanganate;
Step (2): dissolving 0.15-0.75 g of modified potassium permanganate obtained from step (1) in 20 ml of N,N-dimethyl formamide or tetrahydrofuran, then ultrasonically dispersing the mixture for 10-30 minutes to obtain a modified potassium permanganate solution;
Step (3): dissolving 10-20 g of polymer in 60 ml solvents, then swelling the mixture under the temperature of 70-90° C. for 10-14 hours, adding the modified potassium permanganate solution from step (2) into the mixture, stirring it well to remove air bubbles, and then letting it stand for a certain length of time to obtain a mixed solution;
Step (4): coating the mixed solution obtained from step (3) on a glass plate, vacuum drying it under the temperature of 60-70° C. for 15-25 minutes, then drying it under the temperature of 70-90° C. for 4-6 hours in a drum wind dryer, and finally allowing it to cool down naturally.
US Pat. No. 10,138,594

PARTIALLY FLUORINATED URETHANE BASED COATINGS

THE CHEMOURS COMPANY FC, ...

1. A compound for imparting water repellency and optionally stain release to substrates wherein the compound is prepared by the process comprising:reacting (a) at least one isocyanate group-containing compound selected from the group consisting of diisocyanate and polyisocyanate, or mixture thereof; (b) at least one isocyanate-reactive compound selected from the group consisting of cyclic or acyclic sugar alcohol which is substituted with at least two —R1; —C(O)R1; —(CH2CH2O)n(CH(CH3)CH2O)mC(O)R1; or mixtures thereof; where the cyclic or acyclic sugar alcohol is selected from a saccharide, reduced sugar, aminosaccharide, aldonic acid, and aldonic acid lactone;wherein each n is independently 0 to 20;each m is independently 0 to 20;
m+n is greater than 0;
each R1 is independently a linear or branched alkyl group having 5 to 29 carbons optionally comprising at least 1 unsaturated bond; and
(c) at least one fluorinated isocyanate-reactive compound selected from a fluorinated alcohol, fluorinated thiol, or fluorinated amine.
US Pat. No. 10,138,338

COPOLYESTERS PLASTICIZED WITH POLYMERIC PLASTICIZER

Eastman Chemical Company,...

1. A stretched film comprising:(a) a copolyester having a minimum crystallization halftime (t1/2min) of at least 8.6 minutes,
wherein the copolyester comprises:
(i) a diacid component comprising at least 50 mole percent of residues of terephthalic acid, naphthalenedicarboxylic acid, 1,4-cyclohexanedicarboxylic acid, isophthalic acid, or mixtures thereof; and
(ii) a diol component comprising at least 80 mole percent of residues of a diol containing 2 to 10 carbon atoms,
wherein the diacid component is based on 100 mole percent of total diacid residues in the copolyester and the diol component is based on 100 mole percent of total diol residues in the copolyester; and
(b) a polyester plasticizer having a weight-average molecular weight (Mw) of 900 to 12,000 g/mol,
wherein the polyester plasticizer comprises:
(i) a diol component comprising residues of a diol having 2 to 8 carbon atoms; and
(ii) a diacid component comprising residues of a dicarboxylic acid having 4 to 12 carbon atoms;
wherein the film comprises 90 to 99.9 weight percent of the copolyester and 0.1 to 10 weight percent of the polyester plasticizer;
wherein the film has a glass transition temperature of from 40 to 150° C. and the film is stretched at temperatures 5° C. to 80° C. above its glass transition temperature (Tg);
wherein the stretched film has a thickness of 25 to 75 micrometers;
wherein the film is stretched from 2 to 6 times its original measurements; and
wherein the film is clear.
US Pat. No. 10,138,339

SOLAR CELL BACK SHEET FILM AND METHOD FOR PRODUCING THE SAME

FUJIFILM Corporation, To...

1. A film for a solar cell back sheet comprising:a substrate film comprising a polyester, and having a thickness of from 25 ?m to 300 ?m;
a white layer provided directly on at least one surface of the substrate film and comprising a coating film of an aqueous composition for the white layer comprising:
a white pigment,
a first aqueous binder, and
an inorganic oxide filler having a volume average particle size of from 10 nm to 700 nm; and
an adhesive protective layer provided on the white layer and comprising a coating film of an aqueous composition for the adhesive protective layer comprising a second aqueous binder,
wherein:
the white pigment comprises at least one selected from the group consisting of titanium oxide, barium sulfate, aluminum oxide, calcium carbonate, kaolin and talc;
the first aqueous binder comprises at least one selected from the group consisting of polyolefin, polyurethane, polyvinyl alcohol, a polyacrylic and a polyester;
the inorganic oxide filler comprises at least one selected from the group consisting of silica, magnesium oxide and tin oxide;
the second aqueous binder comprises at least one selected from the group consisting of polyolefin, polyurethane, polyvinyl alcohol, a polyacrylic and a polyester; and
the substrate film, the white layer, and the adhesive protective layer are adjacent in this order.
US Pat. No. 10,138,341

USE OF EVAPORATIVE COOLANTS TO MANUFACTURE FILLED POLYURETHANE COMPOSITES

Boral IP Holdings (Austra...

1. A method of making a polyurethane composite, comprising:introducing, in a continuous mold cavity formed by an interior mold surface of two opposed belts, a mixture of:
(1) at least one isocyanate selected from the group consisting of diisocyanates, polyisocyanates, and mixtures thereof,
(2) at least one polyol,
(3) an inorganic filler,
(4) water, and
(5) an evaporative coolant having a boiling point of ?30° C. to 40° C., wherein the evaporative coolant is present in an amount of 0.1% to 2% by weight based on a total weight of polyols in the mixture;
wherein the inorganic filler is dispersed within the mixture to form a cell structure that enables the evaporative coolant to migrate to an interface between the mixture and the interior mold surface;
wherein the at least one isocyanate and the at least one polyol react and generate heat in the mold cavity to form the polyurethane composite, and the temperature of the mixture causes evaporation of the evaporative coolant at the interface thereby removing heat at the interface to reduce surface defects of the polyurethane composite; and
wherein the inorganic filler is present in an amount of 52% to 90% by weight based on a total weight of the polyurethane composite.
US Pat. No. 10,138,598

METHOD OF MAKING A HIGHLY FUNCTIONAL, LOW VISCOSITY KRAFT FIBER USING AN ACIDIC BLEACHING SEQUENCE AND A FIBER MADE BY THE PROCESS

GP Cellulose GmbH, Zug (...

3. The method of claim 1, wherein the catalyst is chosen from at least one of copper and iron, the peroxide is hydrogen peroxide, and the pH of the second and fourth stages ranges from about 2 to about 6.
US Pat. No. 10,137,062

DRY WIPE TO DECREASE FRIZZ, STATIC AND INCREASE SHINE ON HAIR AND AID IN PREVENTION OF REOCCURANCE OF STATIC AND FRIZZ

1. A dry wipe product consisting of:a. a flexible substrate having a first side and a second side; and
b. an anhydrous composition disposed on the first and/or second side(s) of the flexible substrate, the anhydrous composition consisting of:
i. from about 5 wt. % to about 15 wt. % ozokerite;
ii. from greater than 0 wt. % to about 50 wt. % of a fatty ester obtained from a linear or branched chain, saturated, or unsaturated alcohol having from 1 to 24 carbon atoms and a linear or branched chain fatty acid having from 3 to 24 carbon atoms;
iii. from about 15 wt. % to about 35 wt. % of an ester oil selected from the group consisting of a mono-, di- or tri-ester of glycerol;
iv. a second wax;
v. one or more natural oils and/or natural butters;
vi. optionally, one or more polyols;
vii. optionally, one or more solid fatty alcohols;
viii. optionally, one or more amidoamines;
ix. optionally, one or more emulsifiers;
x. optionally, one or more conditioning agents; and
xi. optionally, one or more fragrances.
US Pat. No. 10,138,342

FORMABLE AND FOAMED AQUEOUS COMPOSITIONS

EASTMAN KODAK COMPANY, R...

1. A foamable aqueous composition that has at least 35% solids and up to and including 70% solids, and comprises:(a) at least 0.05 weight % and up to and including 15 weight % of porous particles, each porous particle comprising a continuous polymeric phase and a first set of discrete pores dispersed within the continuous polymeric phase, the porous particles having a mode particle size of at least 2 ?m and up to and including 50 ?m and a porosity of at least 20 volume % and up to and including 70 volume %, and the continuous polymeric phase having a glass transition temperature greater than 80° C. and comprising a polymer having a viscosity of at least 80 centipoises and up to and including 500 centipoises at a shear rate of 100 sec?1 in ethyl acetate at a concentration of 20 weight % at 25° C.,
(b) at least 20 weight % of a binder material;
(c) at least 0.0001 weight % of one or more additives comprising at least one surfactant;
(d) water; and
(e) at least 0.001 weight % of an opacifying colorant different from all of the one or more (c) additives, which opacifying colorant absorbs electromagnetic radiation having wavelengths of from 350 nm to 800 nm,
all amounts based on the total weight of the foamable aqueous composition,
wherein the foamable aqueous composition can provide a dry opacifying layer having a light blocking value of at least 4 as well as a luminous reflectance that is greater than 40% as measured by the Y tristimulus value.
US Pat. No. 10,138,599

PROCESS FOR THE PRODUCTION OF A COATED SUBSTANCE COMPRISING CELLULOSIC FIBRES

STORA ENSO OYJ, Helsinki...

1. A process for the production of a coated substrate comprising cellulosic fibres, the process comprising the steps of:i) providing a first substrate comprising cellulosic fibres and having a dry content of less than 50% by weight;
ii) applying a coating composition to the first substrate in an amount of more than 5 g/m2, calculated as dry weight of the coating composition, wherein the coating composition comprises:
microfibrillated cellulose (MFC), and
a water retention agent selected from carboxymethyl cellulose (CMC), anionic polyacrylamide (A-PAM), sodium polyacrylates, polyacrylic acid derivatives, guar gum, alginate, MFC prepared from carboxymethylated fibers, MFC prepared from oxidized fibers, MFC prepared by CMC-functionalized fibers, and/or combinations thereof; and
iii) mechanically dewatering the first substrate,
wherein the coating composition comprises the water retention agent in an amount of at least 1% by weight, calculated as dry weight and based on the dry weight of the MFC.
US Pat. No. 10,137,063

DYE COMPOSITION COMPRISING NONIONIC GUAR GUM OR A NONIONIC DERIVATIVE THEREOF, PROCESS AND DEVICE FOR THE SAME

1. A composition for dyeing human keratin fibers comprising:at least one oxidation dye precursor;
at least one amphoteric or zwitterionic surfactant;
at least one second surfactant chosen from nonionic surfactants, anionic surfactants, or mixtures thereof;
at least one fatty substance other than ceramides chosen from liquid petroleum jelly, C6-C16 alkanes, polydecenes, or esters of fatty acids or of fatty alcohols, which are liquid, or mixtures thereof; and
at least one nonionic guar gum chosen from modified nonionic guar gums modified with C1-C6 hydroxyalkyl groups.
US Pat. No. 10,138,344

PARTICULATE POLYAMIDE, AND METHOD FOR PREPARING THE PARTICULATE POLYAMIDE

RICOH COMPANY, LTD., Tok...

1. A particulate polyamide comprisingpolyamide 3, wherein
the particulate polyamide is porous and has a particle diameter (d50) of from 10 ?m to 1,000 ?m and a particle diameter dispersion degree (Dv/Dn) of not greater than 3.0, wherein Dv represents a volume average particle diameter of the particulate polyamide and Dn represents a number average particle diameter of the particulate polyamide.
US Pat. No. 10,137,064

FOAMING CLEANSER

1. Composition containing, in a physiologically acceptable medium:a surfactant system comprising (i) at least one N—(C6-30)acyl-amino based surfactant, and (ii) at least one amphoteric surfactant chosen from betaines or (C8-C20)alkyl betaines, (C8-C20)alkylamido(C1-C6)alkylbetaines, and mixtures thereof;
at least one non-associative crosslinked copolymers of (meth)acrylic acid, and of (C1-C4)alkyl esters of (meth)acrylic acid; and
a triglyceride oil,
wherein said N—(C6-C30)acyl-amino based surfactant being present in the surfactant system in a major weight amount, and the surfactant system being present in the composition in an amount of less than 15% by weight relative to the total weight of the composition.
US Pat. No. 10,138,345

PROCESS FOR THE PRODUCTION OF EXPANDED POLYESTER FOAM BEADS

BASF SE, Ludwigshafan am...

1. A process for the production of expanded foam beads, the foam beads prepared from pellets comprising a polyester mixture comprisinga) from 60 to 95% by weight, based on components a and b, of a biodegradable polyester based on aliphatic, or a mixture of aliphatic and aromatic, dicarboxylic acids and on aliphatic diols, and
b) from 5 to 40% by weight, based on components a and b, of polylactic acid,
the process comprising the following steps:
(i) providing a suspension of the polyester pellets in a suspension medium,
(ii) impregnating the pellets in the suspension of step (i) with at least one physical blowing agent to provide a suspension of blowing-agent-loaded pellets, wherein the impregnating includes heating the suspension of pellets to an impregnation temperature in a range from 100 to 140° C., with stirring, and
(iii) depressurizing and cooling the suspension obtained in step (ii)-to provide the expanded foam beads, wherein the depressurization and cooling is carried out with a liquid coolant in a ratio of coolant to suspension medium of 0.3 to 20,
wherein the at least one blowing agent is added in step (i), or in step (ii) during the heating, or after the heating, and
wherein, following the heating of step (ii) and the addition of the at least one blowing agent, the heated suspension is maintained at a temperature in a range from the impregnation temperature minus 5° C. to the impregnation temperature plus 2° C. for a period of 15 to 40 minutes; wherein the biodegradable polyester comprises:
A1) from 30 to 100 mol %, based on components A1) and A2), of one or more of an aliphatic dicarboxylic acid selected from the group consisting of succinic acid, adipic acid, sebacic acid and mixtures thereof,
A2) from 0 to 70 mol %, based on components A1) and A2), of terephthalic acid,
B) from 98.5 to 100 mol %, based on components A1) and A2), of 1,4-butanediol or 1,3-propanediol; and
C) from 0.05 to 1.5% by weight, based on components A1), A2) and B), of one or more compounds selected from the group consisting of:
C1) glycerol,
C2) hexamethylene diisocyanate, and
C3) a di- or polyfunctional epoxide.
US Pat. No. 10,137,065

DEODORANT COMPOSITION AND DEODORANT PRODUCT COMPRISING A DEODORANT COMPOSITION

1. A fluid cosmetic composition which is an antiperspirant and/or deodorant composition to be applied to the human skin, the composition being a non-aluminum based composition free from oils and alcohols as an antiseptic, wherein the composition comprises:from 3.0 to 5.0 weight percent of an alkali metal bicarbonate;
from 0.1 to 1.0 weight percent of sodium carbonate, and
from 0.1 to 3.0 weight percent of sodium sulphate, wherein the alkali metal bicarbonate, sodium carbonate and the sodium sulphate are dissolved in water.
US Pat. No. 10,137,066

CONTROLLED RELEASE ACTIVE AGENT CARRIER

Omya International AG, O...

1. A method for introducing one or more active agents to a target environment comprising contacting the target environment with a pharmaceutical formulation comprising one or more active agents so that the pharmaceutical formulation releases a sufficient quantity of the one or more active agents at the target environment, wherein the pharmaceutical formulation comprises an admixture of: (a) a surface reacted natural calcium carbonate in powder or granule form that is a reaction product of natural calcium carbonate with carbon dioxide and one or more acids in an aqueous environment, wherein the carbon dioxide is formed in situ by the acid treatment and/or is supplied from an external source, and wherein the natural calcium carbonate is marble, calcite, chalk, limestone, or any mixture thereof, (b) one or more active agents adsorbed onto and/or absorbed into the surface-reacted calcium carbonate, and (c) one or more pharmaceutically acceptable carriers.
US Pat. No. 10,137,067

TWO-COMPONENT PRODUCTS IN BAGS FOR THE OXIDATIVE DYEING OF KERATIN FIBRES

1. A product for oxidatively changing the color of keratinic fibers, comprising at least two preparations (A) and (B), which are produced separately from one another, whereinthe first preparation (A) comprises, in a cosmetic carrier,
(A1) hydrogen peroxide and
(A2) at least one chelating agent chosen from the group comprising 1-hydroxyethane-1,1-diphosphonic acid (HEDP), ethylenediaminetetramethylenephosphonic acid (EDTMP), diethylenetriaminepentamethylenphosphonic acid (DTPMP), aminotrimethylenephosphonic acid (ATMP), N,N-bis[2-[bis(carboxymethyl)amino]ethyl]glycine, ethylene-diamine-N,N?-disuccinic acid (EDDS), 2-hydroxypropylenediamine-N,N?-disuccinic acid (HPDDS), ethylenediamine-N,N?-diglutaric acid (EDDG), ethylenediamine-N,N?-bis-(orthohydroxyphenyl)acetic acid (EDDHA),
the second preparation (B), in a cosmetic carrier, comprises
(B1) at least one alkalizing agent,
the preparation (A) is produced in a first container (container A), which comprises at least two layers, wherein
an inner layer of the container A comprises a layer of a synthetic polymer (I) and
an outer layer of the container A comprises a metal layer,
preparation (B) is produced in a second container (container B), which comprises at least two layers, wherein
an inner layer of the container B comprises a layer of a synthetic polymer (I) and
an outer layer of the container B comprises a metal layer, wherein
the first container (container A) is a pouch with a total layer thickness of from about 2 to about 400 ?m (micrometers), and/or
the second container (container B) is a pouch with a total layer thickness of from about 2 to about 400 ?m (micrometers).
US Pat. No. 10,138,348

RESIN COMPOSITION AND CURED PRODUCT THEREOF

OMRON CORPORATION, Kyoto...

1. A resin composition comprising:a bisphenol A epoxy resin;
an encapsulated curing agent including a core that contains a curing agent and a shell that covers the core;
a filler; and
a color material,
the filler having a light-transmitting property and being one or more selected from the group consisting of fused silica, crystalline silica, and glass beads,
the bisphenol A epoxy resin being one or more selected from the group consisting of bisphenol A diglycidyl ether, hydrogenated bisphenol A diglycidyl ether, and tetrabromobisphenol A diglycidyl ether,the filler being contained in an amount that is not less than 10 parts by weight and not more than 70 parts by weight relative to 100 parts by weight of the bisphenol A epoxy resin,the color material being carbon black,
the color material being contained in an amount that is not less than 5 parts by weight and not more than 7 parts by weight relative to 100 parts by weight of the bisphenol A epoxy resin.
US Pat. No. 10,141,169

SYSTEMS AND METHODS FOR IDENTIFYING COMPOUNDS FROM MS/MS DATA WITHOUT PRECURSOR ION INFORMATION

DH Technologies Developme...

1. A system for identifying a compound from tandem mass spectrometry product ions without using any a priori precursor ion information, comprising:a tandem mass spectrometer that analyzes a sample producing at least one measured product ion spectrum from a precursor mass-to-charge ratio range; and
a processor in communication with the tandem mass spectrometer that
(a) receives the at least one measured product ion spectrum from the tandem mass spectrometer,
(b) selects a measured product ion from the at least one measured product ion spectrum,
(c) creates a list of candidate compounds by searching a dictionary of potential compounds with a mass of the measured product ion, wherein the dictionary includes one or more predicted product ions for each of the potential compounds and wherein the dictionary is searched using a key that is a product ion mass to retrieve a list of candidate compounds that could produce the product ion mass,
(d) selects a next measured product ion from the at least one measured product ion spectrum,
(e) creates a next list of candidate compounds by searching the dictionary of potential compounds with a mass of the next measured product ion,
(f) examines all lists of candidate compounds created for candidate compounds common to all the lists, and
(g) repeats steps (d)-(f) until one candidate compound is common to all the lists and identifies the one candidate compound as the identified compound of the product ions selected.
US Pat. No. 10,137,068

METHOD FOR MAINTAINING THE COLOR OF DYED AND/OR HIGHLIGHTED KERATIN FIBRES

1. A method for the color retention of dyed keratin fibers, the method comprising:i. applying a cosmetic composition to dyed keratin fibers as a pretreatment agent for keratin,
and
ii. subjecting the keratin fibers to a dyeing and/or brightening within a period of 5 seconds to 24 hours after to step i.,
wherein the cosmetic composition has, based on its own weight, from 0.01 to 4.00% by weight of at least one alum and a pH value in the range of 2.5 to 5.
US Pat. No. 10,137,324

HALIDE-MEDIATED DEALKYLATION OF PHOSPHOTRIESTERS

Lawrence Livermore Nation...

1. A method, comprising:contacting a phosphotriester and a halogen salt in a polar solvent.
US Pat. No. 10,138,349

MASTER MIXTURE COMPOSITION INCLUDING A PEROXIDE

Arkema France, Colombes ...

1. A thermoplastic composition (I) comprising a copolymer of ethylene and of an ethylenic monomer carrying a polar functional group (a) and a peroxide (b), wherein said composition comprises, by weight,from 5 to 30% of (b);
from 70 to 95% of (a);
wherein the copolymer (a) comprises from 20 to 45% by weight of the ethylenic monomer carrying a polar functional group; and
wherein the thermoplastic composition is transparent.
US Pat. No. 10,137,069

SKIN COSMETIC COMPOSITION, ANTIBACTERIAL AGENT FOR SKIN COSMETIC, AND METHOD FOR ENHANCING ANTIBACTERIAL EFFECT OF DIOL COMPOUND

ADEKA CORPORATION, Tokyo...

1. A skin cosmetic composition comprising: a component (A) which is either hexyl glyceryl ether or both of hexyl glyceryl ether and cyclohexyl glyceryl ether, a component (B) which is either one or both of 1,2-propanediol and 1,3-propanediol, and a component (C) which is one or more compound(s) selected from the group consisting of lactic acid, hydroxyethylethylenediaminetriacetic acid, hydroxyethyliminodiacetic acid, dihydroxyethylglycine, gluconic acid, phytic acid, pentetic acid, etidronic acid, tartaric acid, salts thereof, and gluconolactone,wherein an amount of the component (B) is 1 part by mass to 30 parts by mass and an amount of the component (C) is 0.05 parts by mass to 10 parts by mass with respect to 1 part by mass of the component (A).
US Pat. No. 10,138,350

AQUEOUS EMULSION OF DIALKYL PEROXIDE

ARKEMA FRANCE, Colombes ...

1. Aqueous emulsion of dialkyl peroxide consisting of:at least one dialkyl peroxide in liquid form at room temperature, representing between 10% and 75% by weight of the emulsion,
at least one emulsifier representing from 0.01% to 10% by weight of the emulsion,
optionally, at least one antifreeze,
optionally at least one functional additive,
water, the amount of which is determined so as to form the rest of said emulsion (100%),
wherein the emulsifier is a polyethoxylated nonionic surfactant chosen from the group consisting of ethoxylated carboxylic acid esters, ethoxylated amides, ethoxylated fatty amines, ethoxylated, hydrogenated or non-hydrogenated, plant or animal oils, ethoxylated sorbitan esters, ethoxylated glycerol esters, and combinations thereof, optionally in combination with at least an unethoxylated sorbitan ester, and
wherein the overall HLB (hydrophilic-lipophilic balance) of the emulsifier is between 5 and 12.
US Pat. No. 10,137,070

COMPOSITION INCLUDING IONONE OR SALT THEREOF AS ACTIVE INGREDIENT AND HAVING EFFECT OF ENHANCING SKIN MOISTURIZING, EXFOLIATING SKIN, IMPROVING SKIN ELASTICITY, INHIBITING ERYTHEMA, IMPROVING SKIN WRINKLES, OR ALLEVIATING SKIN PHOTOAGING

YONSEI UNIVERSITY TECHNOL...

1. A method of enhancing skin moisturizing, exfoliating skin,improving skin elasticity, inhibiting erythema, improving skin wrinkles, and/or alleviating skin photoaging, the method comprising administering or taking a composition comprising:
a skin active ingredient consisting of ionone or a pharmaceutically acceptable or consisting of ionone or a pharmaceutically acceptable salt thereof and vitamin C; and
a carrier,
wherein the composition i) increases the level of PIP(procollagen type I C-peptide), ii) increases the expression level of Collagen Type 1?1, 1?2, 3?1, or iii) decreases the expression level of MMP-1a, MMP-3, and MMP-9.
US Pat. No. 10,138,351

RUBBER COMPOSITIONS AND USES THEREOF

Bridgestone Corporation, ...

1. A rubber composition comprising:(a) 50-100 phr of at least one polymer or copolymer selected from the group consisting of synthetic conjugated diene monomer-containing polymers, synthetic conjugated diene monomer-containing copolymers, and combinations thereof;
(b) 0-50 phr of at least one polymer or copolymer selected from the group consisting of monoolefin-containing polymers, copolymers of at least one monoolefin and at least one alpha-olefin, and combinations thereof;
(c) 1-10 phr of at least one nucleating agent having formula (I)
M2(O2CR)4  (I)
where M is a transition metal selected from the group consisting of scandium, titanium, vanadium, chromium, manganese, iron, cobalt, nickel, copper, zinc, yttrium, zirconium, niobium, molybdenum, ruthenium, rhodium, palladium, silver, cadmium, hafnium, tantalum, tungsten, rhenium, osmium, iridium, platinum, gold, mercury, and iridium and R is selected from C3-C18 alkyl;
(d) 1 to 20 phr of at least one processing oil;
(e) 0-100 phr of at least one reinforcing filler and
(f) a cure package including a vulcanizing agent consisting of a sulfur-based curative,
wherein upon curing the rubber composition meets at least one of (i) or (ii), as follows:
(i) exhibits reduced wear as exhibited by having a wear index (measured at a slip percentage of 25%) that is 110% or higher, based upon a comparative rubber compound that contains no nucleating agent of formula (I) but contains additional processing oil in a phr amount equal to the amount of the at least one nucleating agent of formula (I), and
(ii) exhibits strain-induced crystallization.
US Pat. No. 10,137,071

NITRONE INHIBITION OF OXIDATION OF UNSATURATED FATS

Dow Global Technologies L...

1. A method for inhibiting oxidation of an unsaturated fat, wherein the unsaturated fat is at least one of linoleic acid and/or linolenic acid, comprising blending the unsaturated fat with an effective amount of an antioxidant compound selected from the group consisting of (Z)-N-(4-hydroxy-3-methoxybenzylidene)propan-2-amine, (Z)-N-(4-hydroxybenzylidene)propan-2-amine oxide, and combinations thereof.
US Pat. No. 10,137,072

METHODS AND COMPOSITIONS FOR PROVIDING BROAD SPECTRUM PHOTO PROTECTION USING ANTIOXIDANTS

1. A method for providing at least broad spectrum photo protection to skin, which includes protection from infrared radiation and visible light, the method comprising topically applying to the skin of a subject a cosmetic composition comprising:(a) 0.001 to 20 wt. %, based on the total weight of the composition of one or more antioxidants selected from the group consisting of baicalin, thermus thermophillus ferment, ferulic acid, polydatin, silymarin, punica granatum extract, mango leaf extract, catechin, hesperetin, astilbin, and DHC V;
(b) 0.001 wt. % to 30 wt. % of one or more cosmetically acceptable hydrotropes selected from the group consisting of nicotinamide, caffeine, sodium PCA, sodium salicylate, urea, and hydroxyethyl urea; and
(c) a cosmetically acceptable carrier;
wherein the combination of (a), (b), and (c) alone provides at least broad spectrum protection from both infrared radiation and visible light.
US Pat. No. 10,138,353

CROSSLINKABLE POLYMERIC COMPOSITIONS WITH N,N,N?,N?,N?,N?-HEXAALLYL-1,3,5-TRIAZINE-2,4,6-TRIAMINE CROSSLINKING COAGENT, METHODS FOR MAKING THE SAME, AND ARTICLES MADE THEREFROM

Dow Global Technologies L...

1. A crosslinkable polymeric composition, comprising:(a) a thermoplastic, non-elastomer ethylene-based polymer that is a low-density polyethylene;
(b) an organic peroxide; and
(c) a crosslinking coagent comprising N,N,N?,N?,N?,N?-hexaallyl-1,3,5-triazine-2,4,6-triamine.
US Pat. No. 10,137,073

COSMETIC COMPOSITIONS COMPRISING CERAMIDES AND CHOLESTEROL

1. A ready to use cosmetic composition in the form of an emulsion comprising:(a) 2 wt. % to 8 wt. % of cholesterol, based on the total weight of the cosmetic composition;
(b) 1 wt. % to 5 wt. % of non-crystallized ceramide-3 and non-crystallized ceramide-EOP, based on the total weight of the cosmetic composition,
wherein the ratio of (a) to (b) is 1.5:1.0 to 5:1.0;
(c) one or more silicone oils and one or more hydrocarbon based oils;
(d) 0.5 wt. % to 10 wt. % of one or more organosiloxane emulsifiers;
(e) 0.1 wt. % to 10 wt. % of one or more thickeners; and
(f) 45 wt. % to 65 wt. % of water, based on the total weight of the cosmetic composition.
US Pat. No. 10,138,354

POLYMER COMPOSITION HAVING DELAYED CRYSTALLIZATION BEHAVIOR, ADDITIVE COMPOSITION THAT INFLUENCES THE CRYSTALLIZATION BEHAVIOR, METHOD FOR REDUCING THE CRYSTALLIZATION POINT AND/OR THE CRYSTALLIZATION SPEED, AND USE OF AN ADDITIVE COMPOSITION

1. A polymer composition, comprising or consisting ofa) a matrix made of at least one crystallisable, thermoplastic polymer,
b) at least one azine dye, and
c) at least one mono-, bi-, tri- and/or tetravalent metal salt, selected from the group consisting of metal chlorides, metal bromides and metal pseudohalogenides, mixtures thereof, and combinations thereof.
US Pat. No. 10,137,074

COSMETIC COMPOSITION AND METHODS OF USE THEREOF

Mary Kay Inc., Addison, ...

1. A cosmetic composition comprising:35 to 45% by weight of sucrose;
7 to 15% by weight of Butyrospermum parkii (shea) butter;
13 to 20% by weight of tridecyl trimellitate;
2 to 12% by weight of glycerin;
2 to 12% by weight of Helianthus annuus (sunflower) seed oil;
2 to 12% by weight of caprylic/capric triglyceride;
1 to 6% by weight of trihydroxystearin;
0.5 to 5% by weight of glyceryl stearate; and
a dermatologically acceptable vehicle.
US Pat. No. 10,137,075

COSMETIC USE OF AN EXTRACT OF BALANITES ALMONDS TO IMPROVE HAIR STRENGTH

PIERRE FABRE DERMO-COSMET...

1. A topical cosmetic composition for improving hair strength comprising an effective amount of a hydro-alcoholic Balanites almond extract as an active agent and an effective amount of an added preservative, wherein the Balanites almond extract includes the following contents expressed as percentages by weight with respect to the extract without a drying medium:waxes: from 1% to 10%,
free amino acids: 1% to 5%,
proteins: from 0.5% to 10%, and
total sugars: from 20% to 60%,wherein the cosmetic composition is in the form of a shampoo, a balm, a mask, a gel, a lotion, a foam, a spray or a cream.
US Pat. No. 10,137,076

MASSAGE OIL AND METHOD OF MANUFACTURE

1. A method of manufacturing a message oil, comprising:adding:
Bay leaves;
St. John's Wort;
Mugwort;
Lavender flower;
Chamomile flower;
Yerba Santa; and
Arnica Flower to Virgin Olive oil;
in a low temperature cooker;
setting the cooker to 209 degrees; covering and cooking for 12 hours;
leaving the cooker covered for 30 days;
after 30 days, straining out all botanical materials and adding bay essential oil, vetivert essential oil, chamomile essential oil, ylang yland essential oil, and lavender add essential oil; and mixing well.
US Pat. No. 10,138,357

RESIN COMPOSITION AND RESIN SHAPED PRODUCT

FUJI XEROX CO., LTD., To...

1. A resin composition comprising:a cellulose ester resin;
a compound containing an adipic acid ester; and
a polyhydroxyalkanoate resin.
US Pat. No. 10,137,077

COSMETIC USE OF ARTEMIA SALINA EXTRACT TO PROTECT SKIN FROM THERMAL STRESS

ISP Investments, LLC, Wi...

1. A method of cosmetic care to protect the skin of a human or animal from damage due to cold thermal stress, the method comprising:topically applying at least once or twice daily for at least two days, on at least one portion of the skin of the body or face of the human or animal which has been subjected to cold thermal stress, a composition comprising a physiologically acceptable medium and an Artemia salina extract obtained from rehydrated Artemia salina cysts,
wherein the Artemia salina extract is present in the composition at a concentration of about 0.0001% to about 20% of the total weight of the composition, and the cells of the at least one portion of skin of the body or face of the human or animal maintain a physiological level of cold-inducible RNA-binding protein.
US Pat. No. 10,138,358

MOLDABLE COMPOSITIONS AND METHODS OF USING THE SAME

CRAYOLA LLC, Easton, PA ...

1. A moldable composition comprising:water,
at least one polar polymeric resin,
at least one thickening agent comprising:
guar gum,
xanthan gum, and
a borate salt or hydrate of a borate salt, wherein the borate salt or the hydrate of a borate salt is selected from the group consisting of ammonium borate, zinc borate, sodium borate, and ammonium pentaborate tetrahydrate,
at least one humectant,
at least one filler excluding microsphere fillers,
optionally at least one releasing agent and
optionally at least one additive.
US Pat. No. 10,137,334

GOLF BALL MANUFACTURING METHOD

Bridgestone Sports Co., L...

1. A method of manufacturing a golf ball having a core and a cover of one or more layer over the core, wherein an outermost layer of the cover is molded of a thermoplastic material selected from the group consisting of polyurethane, polyurea and mixtures thereof, the method comprising at least the following steps (1) and (2):(1) treating a surface of the cover with an isocyanate compound; and
(2) washing off and physically removing excess isocyanate compound by using a specific substance, and wherein, when an infrared absorption spectrum measured by FT-IR/ATR spectroscopy at an outside portion of the outermost cover layer of the golf ball manufactured by steps (1) and (2) is plotted as absorbance versus wave number, letting the absorbance peak heights near the wave numbers 1512 cm?1, 2280 cm?1 and 2840 cm?1 be respectively P1, Q1 and R1, the value Q1/R1 is larger than P1,
wherein in step (2), the specific substance is used by blasting the cover surface with the specific substance at a temperature of at least 5° C.
US Pat. No. 10,137,590

AUTOMATED APPLICATION OF CUT THERMAL ADHESIVE FILMS

ZAZZLE INC., Redwood Cit...

1. A method of manufacturing a tangible substrate with a thermal film that is cut according to computer instructions, the method comprising:obtaining an input digital image of a design that is to be transferred to the tangible substrate and storing the input digital image in electronic digital memory of a computer;
using the computer, rendering a plurality of design elements of the design as a single output image;
using the computer and based upon the output image, a bleed size value, a maximum number of negative areas, a maximum number of positive areas, and one or more substrate attribute values: resizing the output image to include a border for bleed; filling all transparent areas of the output image with the one or more substrate attribute values; creating and storing a cutting path;
creating and storing a mask image;
digitally inverting the mask image in the memory;
modifying the mask image to adjust one or more fill areas around one or more details, to limit negative areas to be less than the maximum number of negative areas, and to limit positive areas to be less than the maximum number of positive areas, resulting in a modified mask image;
creating and storing cutting path data in the memory, comprising a vector path on an outline of the mask image;
transmitting the cutting path data over a computer network.
US Pat. No. 10,138,359

RUBBER COMPOSITION FOR TIRES AND PNEUMATIC TIRE

SUMITOMO RUBBER INDUSTRIE...

1. A rubber composition for tires, comprising a modified natural rubber, the modified natural rubber prepared by treating natural rubber latex with a proteolytic enzyme, and then treating the treated natural rubber latex with at least one of a lipolytic enzyme or a phospholipid degrading enzyme.
US Pat. No. 10,137,079

TRANSDERMAL COMPOSITION FOR TREATING PAIN

CURA HEALTH INC., Missis...

1. A transdermal ethosome composition comprising:an alcohol;
a phospholipid;
a glycol;
water; and
a magnesium salt.
US Pat. No. 10,138,360

RUBBER COMPOSITION FOR VIBRATION DAMPING RUBBERS, AND VIBRATION DAMPING RUBBER

1. A rubber composition for vibration damping rubbers, comprising:a rubber component which comprises at least one selected from the group consisting of natural rubbers and polyisoprene rubbers in an amount of 60 to 95 parts by weight, and which comprises a styrene butadiene rubber in an amount of 5 to 30 parts by weight; and
a complex zinc flower in an amount of 2 to 10 parts by weight for 100 parts by weight of the rubber component;
wherein the complex zinc flower has a nitrogen adsorption specific surface area of 15 to 110 m2/g, a DBP oil absorption amount of 50 to 100 mL/100 g, and a zinc flower concentration of 38 to 64% by weight.
US Pat. No. 10,137,080

METHOD OF STABILIZING ANTIBODY AND STABILIZED SOLUTION-TYPE ANTIBODY PREPARATION

KYOWA HAKKO KIRIN CO., LT...

1. A solution-type antibody preparation comprising an antibody, 10 to 30 mg/mL glycine, and 0.1 to 50 mmol/L citric acid, wherein the formation of soluble associations and chemically degraded products of said antibody are inhibited in said preparation,wherein said preparation has at least one of the following features (a) and (b):
(a) said preparation contains between 0.1 to 1 mg/mL of non-ionic surfactant; and
(b) said preparation does not contain polyethylene glycol.
US Pat. No. 10,138,361

RUBBER COMPOSITION AND PNEUMATIC TIRE

SUMITOMO RUBBER INDUSTRIE...

1. A rubber composition, comprising:5 to 150 parts by mass of carbon black;
10 to 150 parts by mass of silica, wherein the silica comprises silica (1) that has a nitrogen adsorption specific surface area in the range 50 m2/g to less than 120 m2/g and silica (2) that has a nitrogen adsorption specific surface area of 120 m2/g or more;
100 parts by mass of a rubber component comprising styrene butadiene rubber; and
5 to 50 parts by mass of a modified polymer obtained by modifying a styrene-butadiene copolymer, wherein the modified polymer contains a moiety -(A)-C(O)R1 in which R1 is —OR4 or —B—(CO)OR5, A and B being, independently, a divalent saturated or unsaturated hydrocarbon group and R4 and R5 being, independently, hydrogen or a divalent saturated or unsaturated hydrocarbon group, and wherein the modified polymer has a weight average molecular weight of from 1000 to 100,000,
wherein the rubber composition has a tan? peak temperature of ?20° C. or higher, a rubber hardness of from 63 to 75, and a tan? at 70° C. of from 0.15 to 0.45.
US Pat. No. 10,139,385

METHOD OF TRACING CHEMICAL QUANTITIES USING ENCAPSULATED FLUORESCENT DYES

Ecolab USA Inc., Napervi...

1. A method of treating wastewater comprising introducing into wastewater (a) an aluminum salt and (b) an encapsulated tracer comprising a capsule encapsulating a core, the core comprising a xanthene derivative selected from Rhodamine WT and Rhodamine B, and the capsule comprising a polyethhylene oxide-polypropylene oxide-polyethylene oxide (“PEO-PPO-PEO”) tri-block copolymer, the encapsulated tracer introduced into the wastewater in a dosage such that the amount of aluminum salt introduced to the wastewater can be determined from fluorescence of the xanthene derivative present in the encapsulated tracer, wherein the xanthene derivative and the PEO-PPO-PEO tri-block copolymer are present in the encapsulated tracer at a ratio of from 1:20 to 3:10 by weight, and the wastewater has a pH of 6 or less.
US Pat. No. 10,137,081

DEVICE AND METHOD FOR SUSTAINED RELEASE OF ANTIPSYCHOTIC MEDICATIONS

Delpor, Inc., San Franci...

1. A drug delivery device, comprising:a non-erodible, non-porous housing member defining a reservoir, said housing member having first and second opposing ends;
a porous partition positioned in the housing member; and
contained within said reservoir, a drug formulation comprised of a salt form of risperidone selected from the group consisting of risperidone octanoate, risperidone hexanoate and risperidone pentanoate, wherein the drug formulation when hydrated releases risperidone at a rate that provides a therapeutic dose over a period of at least about 2 months.
US Pat. No. 10,138,362

ETHYLENE-BASED POLYMER COMPOSITION FOR FILMS WITH IMPROVED TOUGHNESS

Dow Global Technologies L...

1. A composition comprising a first composition, comprising at least one ethylene-based polymer, and wherein the first composition comprises a MWCDI value greater than 1.2, and a melt index ratio (I10/I2) that meets the following equation: I10/I2?7.0?1.2×log (I2).
US Pat. No. 10,137,082

HYDROGEL MICROPARTICLE SCAFFOLD WITH GRADIENTS OF DEGRADABILITY AND METHODS THEREOF

Washington University, S...

1. A modular scaffold comprising a plurality of hydrogel microparticles, wherein the hydrogel microparticles are crosslinked together with at least some crosslinks having tunable rates of enzymatic degradation, wherein the crosslinks is the plasmin sensitive peptide sequence Ac-GCGGVRNGGK-NH2.
US Pat. No. 10,137,083

OPHTHALMIC PREPARATIONS

SGN Nanopharma Inc, Tamp...

1. An ophthalmic nanoemulsion formulation comprising:(a) a cyclosporine selected from the group consisting of cyclosporines A, B, C, D and G,
(b) ethanol,
(c) at least one oil, wherein the oil comprises medium chain triglycerides,
(d) at least one surfactant, wherein the surfactant is a polysorbate,
(e) at least one cationic preservative, and
(f) water or phosphate buffered saline,
wherein (i) the cyclosporine is in a solid particulate state and in a soluble state, (ii) the cyclosporine in the solid particulate state is present in the water or the phosphate buffered saline, (iii) the formulation is phospholipid-free, and (iv) the formulation comprises globules of oil comprising dissolved cyclosporine, wherein the globules have a mean diameter between 100 and 250 nm,
wherein the at least one cationic preservative is selected from the group consisting of cetyltrimethylammonium bromide, cetylpyridinium chloride, benzethonium chloride, and benzalkonium chloride.